Pa Schedule W 2s: Fill & Download for Free

They haven’t been dismissed without thought. We’ve spent many millions of dollars looking into their claims. Research money that arguably could have been better spent elsewhere. Here’s some of the studies looking at vaccine safety.Conclusion (with evidence): they’re safe.Hanson KE, McLean HQ, Belongia EA, Stokley S, McNeil MM, Gee J, VanWormer JJ. Sociodemopgrahic and clinical correlates of human papillomavirus vaccine attitudes and receipt among Wisconsin adolescentsexternal icon. Papillomavirus Res. 2019 Dec; 8: 100168; Epub 2019 May 25.Kochhar S, Edwards KM, Ropero Alvarez AM, Moro PL, Ortiz JR. Introduction of new vaccines for immunization in pregnancy – Programmatic, regulatory, safety and ethical considerationsexternal icon. Vaccine. 2019 May 31; 37(25): 3267-3277. Epub 2019 May 6.DeStefano F, Shimabukuro TT. The MMR Vaccine and Autism.external iconAnnu Rev Virol. 2019 Sep; 6. Epub 2019 Apr 15.Zheng C, Yu W, Xie F, Chen W, Mercado C, Sy LS, Qian L, Glenn S, Lee G, Tseng HF, Duffy J, Jackson LA, Daley MF, Crane B, McLean HQ, Jacobsen SJ. The use of natural language processing to identify Tdap-related local reactions at five health care systems in the Vaccine Safety Datalinkexternal icon, International Journal of Medical Informatics, 2019 Jul; 127(1386-5056): 27-34. Epub 2019 Apr 13.Myers TR, McCarthy NL, Panagiotakopoulos L, Omer SB. Estimation of the Incidence of Guillain-Barré Syndrome During Pregnancy in the United Statesexternal icon. Open Forum Infectious Diseases. 2019 Mar; 6(3): ofz071.Klein NP, Goddard K, Lewis E, Ross P, Gee J, DeStefano F, Baxter R. Long term risk of developing type 1 diabetes after HPV vaccination in males and females.external iconVaccine. 2019 Mar 28; 37(14):1938-1944. Epub 2019 Mar 1.Hesse EM, Shimabukuro TT, Su JR, et al. Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) — United States, October 2017–June 2018. MMWR Morb Mortal Wkly Rep 2019 Feb 1; 68(4):91–94.Landazabal CS, Moro PL, Lewis P, Omer SB. Safety of 9-valent human papillomavirus vaccine administration among pregnant women: Adverse event reports in the Vaccine Adverse Event Reporting System (VAERS), 2014-2017external icon. Vaccine. 2019 Feb 21; 37(9):1229-1234. Epub 2019 Jan 16.Su JR, Moro PL, Ng CS, Lewis PW, Said MA, Cano MV. Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System, 1990-2016.external iconJ Allergy Clin Immunol. 2019 Apr; 143(4):1465-1473. Epub 2019 Jan 14.Tartof SY, Qian L, Liu IA, Tseng HF, Sy LS, Hechter RC, Lewin BJ, Jacobsen SJ. Safety of Influenza Vaccination Administered During Hospitalizationexternal icon. Mayo Clin Proc. 2019 Mar; 94(3):397-407. Epub 2019 Jan 8.2018McClure DL, Jacobsen SJ, Klein NP, Naleway AL, Kharbanda EO, Glanz JM, Jackson LA, Weintraub ES, McLean HQ. Similar relative risks of seizures following measles containing vaccination in children born preterm compared to full-term without previous seizures or seizure-related disordersexternal icon. Vaccine. 2019 Jan 3; 37(1):76-79. Epub 2018 Nov 23.Myers TR, McNeil MM, Current safety issues with quadrivalent meningococcal conjugate vaccines.external iconHum Vaccin Immunother, 2018 May 4; 14(5): 1175-1178; Epub 2017 Nov 8.Moro PL, Lewis P, Cano M Adverse events following purified chick embryo cell rabies vaccine in the Vaccine Adverse Event Reporting System (VAERS) in the United States, 2006-2017 – Correspondenceexternal iconTravel Medicine and Infectious Disease 2019 May-Jun; 29(1477-8939): 80-81. Epub 2018 Oct 26.Suragh TA, Lewis P, Arana J, Mba-Jonas A, Li R, Stewart B, Shimabukuro TT, Cano M. Safety of bivalent human papillomavirus vaccine in the US vaccine adverse event reporting system (VAERS), 2009-2017.external iconBr J Clin Pharmacol. 2018 Dec; 84(12):2928-2932. Epub 2018 Sep 21.Fortner KB, Swamy GK, Broder KR, Jimenez-Truque N, Zhu Y, Moro PL, Liang J, Walter EB, Heine RP, Moody MA, Yoder S, Edwards KM. Reactogenicity and immunogenicity of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant and nonpregnant womenexternal icon. Vaccine. 2018 Oct 8; 36(42):6354-6360. Epub 2018 Sep 13.Groom HC, Irving SA, Koppolu P, Smith N, Vazquez-Benitez G, Kharbanda EO, Daley MF, Donahue JG, Getahun D, Jackson LA, Tse Kawai A, Klein NP, McCarthy NL, Nordin JD, Sukumaran L, Naleway AL. Uptake and safety of Hepatitis B vaccination during pregnancy: A Vaccine Safety Datalink studyexternal icon. Vaccine. 2018 Oct 1; 36(41):6111-6116. Epub 2018 Sep 5.Naleway AL, Mittendorf KF, Irving SA, Henninger ML, Crane B, Smith N, Daley MF, Gee J. Primary Ovarian Insufficiency and Adolescent Vaccinationexternal icon. Pediatrics. 2018 Sep; 14(3). Epub 2018 Aug 21.Haber P, Amin M, Ng C, Weintraub E, McNeil MM. Reports of lower respiratory tract infection following dose 1 of RotaTeq and Rotarix vaccines to the Vaccine Adverse Event Reporting System (VAERS), 2008-2016external icon. Hum Vaccin Immunother. 2018 Jul 11:1-5. Epub 2018 Jul 26.Kharbanda EO, Vazquez-Benitez G, Lipkind HS, Sheth SS, Zhu J, Naleway AL, Klein NP, Hechter R, Daley MF, Donahue JG, Jackson ML, Kawai AT, Sukumaran L, Nordin JD. Risk of Spontaneous Abortion After Inadvertent Human Papillomavirus Vaccination in Pregnancyexternal icon. Obstet. Gynecol. 2018 Jul; 132(1): 35-44.Su JR, Ng C, Lewis PW, Cano MV. Adverse events after vaccination among HIV-positive persons, 1990-2016.external iconPLoS One. 2018 Jun 19; 13(6) e0199229.Walker WL, Hills SL, Miller ER, Fischer M, Rabe IB. Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2012-2016external icon. Vaccine. 2018 Jul 5; 36(29):4369-4374. Epub 2018 Jun 8.Moro PL, Perez-Vilar S, Lewis P, Bryant-Genevier M, Kamiya H, Cano M. Safety Surveillance of Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) Vaccinesexternal icon. Pediatrics. 2018 Jul; 142(1). Epub 2018 Jun 4.Jackson ML, Yu O, Nelson JC, Nordin JD, Tartof SY, Klein NP, Donahue JG, Irving SA, Glanz JM, McNeil MM, Jackson LA. Safety of repeated doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine in adults and adolescentsexternal icon. Pharmacoepidemiol. Drug Saf. 2018 Aug; 27(8): 921-925. Epub 2018 Jun 3.Tseng HF, Sy LS, Qian L, Liu IA, Mercado C, Lewin B, Tartof SY, Nelson J, Jackson LA, Daley MF, Weintraub E, Klein NP, Belongia E, Liles EG, Jacobsen SJ. Pneumococcal Conjugate Vaccine Safety in Elderly Adultsexternal icon. Open. Forum Infect. Dis. 2018 May 2; 5(6): ofy100. Epub 2018 Jun.Shimabukuro TT, Miller ER, Strikas RA, Hibbs BF, Dooling K, Goud R, Cano MV Notes from the Field: Vaccine Administration Errors Involving Recombinant Zoster Vaccine — United States, 2017–2018. MMWR Morb Mortal Wkly Rep 2018 May 25; 67: 585–586.Miller ER, Lewis P, Shimabukuro TT, Su J, Moro P, Woo EJ, Jankosky C, Cano M. Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015external icon. Hum Vaccin Immunother. 2018 Mar 26; 14(8): 1963-1969 Epub 2018 May 18.Xu S, Clarke CL, Newcomer SR, Daley MF, Glanz JM. Analyzing self-controlled case series data when case confirmation rates are estimated from an internal validation sampleexternal icon. Biom. J. 2018 Jul; 60(4): 748-760. Epub 2018 May 16.Zerbo O, Modaressi S, Goddard K, Lewis E, Fireman BH, Daley MF, Irving SA, Jackson LA, Donahue JG, Qian L, Getahun D, DeStefano F, McNeil MM, Klein NP. Vaccination Patterns in Children After Autism Spectrum Disorder Diagnosis and in Their Younger Siblingsexternal icon. JAMA Pediatr. 2018 May 1; 172(5): 469-475.Liang JL, Tiwari T, Moro P, Messonnier NE, Reingold A, Sawyer M, Clark TA. Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2018 Apr 27 ;67(No. RR-2):1–44.Donahue, J. Response to three Letters to the Editor regarding: Donahue JG, et al. Association of spontaneous abortion with receipt of inactivated influenza vaccine containing H1N1pdm09 in 2010-11 and 2011-12external icon. Vaccine. 2018 Apr 19; 36(17): 2231-2232.Daley MF, Shoup JA, Newcomer SR, Jackson ML, Groom HC, Jacobsen SJ, McLean HQ, Klein NP, Weintraub ES, McNeil MM, Glanz JM. Assessing Potential Confounding and Misclassification Bias When Studying the Safety of the Childhood Immunization Scheduleexternal icon. Acad. Pediatr. 2018 Sept – Oct; 18(7): 754-762. Epub 2018 Mar 28.Glanz JM, Newcomer SR, Daley MF, DeStefano F, Groom HC, Jackson ML, Lewin BJ, McCarthy NL, McClure DL, Narwaney KJ, Nordin JD, Zerbo O. Association Between Estimated Cumulative Vaccine Antigen Exposure Through the First 23 Months of Life and Non-Vaccine-Targeted Infections From 24 Through 47 Months of Ageexternal icon. JAMA. 2018 Mar 6; 319(9): 906-913.Irving SA, Groom HC, Stokley S, McNeil MM, Gee J, Smith N, Naleway AL. Human Papillomavirus Vaccine Coverage and Prevalence of Missed Opportunities for Vaccination in an Integrated Healthcare Systemexternal icon. Acad. Pediatr. 2018 Mar; 18(2S): S85-S92.Kuntz J, Crane B, Weinmann S, Naleway AL. Myocarditis and pericarditis are rare following live viral vaccinations in adultsexternal icon. Vaccine. 2018 Mar 14; 36(12): 1524-1527. Epub 2018 Feb 15.Markowitz LE, Gee J, Chesson H, Stokley S. Ten Years of Human Papillomavirus Vaccination in the United States.external iconAcad Pediatr. 2018 Mar; 18(2S):S3-S10.Arana JE, Harrington T, Cano M, Lewis P, Mba-Jonas A, Rongxia L, Stewart B, Markowitz LE, Shimabukuro TT. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015external icon. Vaccine. 2018 Mar 20; 36(13):1781-1788. Epub 2018 Feb 21.Sukumaran L, McCarthy NL, Kharbanda EO, Vazquez-Benitez G, Lipkind HS, Jackson L, Klein NP, Naleway AL, McClure DL, Hechter RC, Kawai AT, Glanz JM, Weintraub ES. Infant Hospitalizations and Mortality After Maternal Vaccinationexternal icon. Pediatrics. 2018 Mar; 14(3). Epub 2018 Feb 20.Li R, Weintraub E, McNeil MM, Kulldorff M, Lewis EM, Nelson J, Xu S, Qian L, Klein NP, DeStefano F. Meningococcal conjugate vaccine safety surveillance in the Vaccine Safety Datalink using a tree-temporal scan data mining methodexternal icon. Pharmacoepidemiol. Drug Saf. 2018 Apr; 27(4): 391-397. Epub 2018 Feb 15.Zhou H, Thompson WW, Belongia EA, Fowlkes A, Baxter R, Jacobsen SJ, Jackson ML, Glanz JM, Naleway AL, Ford DC, Weintraub E, Shay DK. Estimated rates of influenza-associated outpatient visits during 2001-2010 in six US integrated health care delivery organizationsexternal icon. Influenza. Other Respir. Viruses. 2018 Jan; 12(1): 122-131. Epub 2018 Feb 15.McNeil MM, DeStefano F. Vaccine-associated hypersensitivityexternal icon. J. Allergy Clin. Immunol. 2018 Feb; 141(2): 463-472.Newcomer SR, Kulldorff M, Xu S, Daley MF, Fireman B, Lewis E, Glanz JM. Bias from outcome misclassification in immunization schedule safety researchexternal icon. Pharmacoepidemiol. Drug Saf. 2018 Feb; 27(2): 221-228. Epub 2018 Jan 2.2017Tamez RL, Tan WV, O’Malley JT, Broder KR, Garzon MC, LaRussa P, Lauren CT. Influenza B virus infection and Stevens-Johnson syndrome. external iconPediatr Dermatol. 2018 Jan; 35(1):e45-e48. Epub 2017 Dec 28.Storms AD, Chen J, Jackson LA, Nordin JD, Naleway AL, Glanz JM, Jacobsen SJ, Weintraub ES, Klein NP, Gargiullo PM, Fry AM. Rates and risk factors associated with hospitalization for pneumonia with ICU admission among adultsexternal icon. BMC. Pulm. Med. 2017 Dec 16; 17(1): 208.Hibbs BF, Miller E, Shi J, Smith K, Lewis P, Shimabukuro TT. Safety of vaccines that have been kept outside of recommended temperatures: Reports to the Vaccine Adverse Event Reporting System (VAERS), 2008-2012external icon. Vaccine. 2018 Jan 25; 36(4):553-558. Epub 2017 Dec 14.Haber P, Moro PL, Ng C, Lewis PW, Hibbs B, Schillie SF, Nelson NP, Li R, Stewart B, Cano MV. Safety of currently licensed hepatitis B surface antigen vaccines in the United States, Vaccine Adverse Event Reporting System (VAERS), 2005-2015external icon. Vaccine. 2018 Jan 25; 36(4):559-564. Epub 2017 Dec 11.Groom HC, Irving SA, Caldwell J, Larsen R, Beaudrault S, Luther LM, Naleway AL. Implementing a Multipartner HPV Vaccination Assessment and Feedback Intervention in an Integrated Health Systemexternal icon. J. Public Health Manag. Pract. 2017 Nov/Dec; 23(6): 589-592.Loharikar A, Suragh TA, MacDonald NE, Balakrishnan MR, Benes O, Lamprianou S, Hyde TB, McNeil MM. Anxiety-related adverse events following immunization (AEFI): A systematic review of published clusters of illnessexternal icon. Vaccine. 2018 Jan 4; 36(2):299-305. Epub 2017 Nov 29.Moro PL, Zheteyeva Y, Barash F, Lewis P, Cano M. Assessing the safety of hepatitis B vaccination during pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 1990-2016external icon. Vaccine. 2018 Jan 2; 36(1):50-54. Epub 2017 Nov 27.Daley MF, Clarke CL, Glanz JM, Xu S, Hambidge SJ, Donahue JG, Nordin JD, Klein NP, Jacobsen SJ, Naleway AL, Jackson ML, Lee G, Duffy J, Weintraub E. The safety of live attenuated influenza vaccine in children and adolescents 2 through 17 years of age: A Vaccine Safety Datalink studyexternal icon. Pharmacoepidemiol Drug Saf. 2018 Jan; 27(1): 59-68. Epub 2017 Nov 17.Kemper AR, Barnett ED, Walter EB, Hornik C, Pierre-Joseph N, Broder KR, Silverstein M, Harrington T. Drinking Water to Prevent Postvaccination Presyncope in Adolescents: A Randomized Trial. external iconPediatrics 2017 Nov; 140(5).Arana J, Mba-Jonas A, Jankosky C, Lewis P, Moro PL, Shimabukuro TT, Cano M. Reports of Postural Orthostatic Tachycardia Syndrome After Human Papillomavirus Vaccination in the Vaccine Adverse Event Reporting Systemexternal icon. J Adolesc Health. 2017 Nov; 61 (5): 577-582.Stockwell MS, Marchant CD, Wodi AP, Barnett ED, Broder KR, Jakob K, Lewis P, Kattan M, Rezendes AM, Barrett A, Sharma D, Fernandez N, LaRussa P. A multi-site feasibility study to assess fever and wheezing in children after influenza vaccines using text messaging. external iconVaccine. 2017 Dec 15; 35(50):6941-6948. Epub 2017 Oct 28.Izurieta HS, Moro PL, Chen RT. Hospital-based collaboration for epidemiological investigation of vaccine safety: A potential solution for low and middle-income countries? external iconVaccine. 2018 Jan 8; 36(3):345-346. Epub 2017 Oct 21.McCarthy NL, Sukumaran L, Newcomer S, Glanz J, Daley MF, McClure D, Klein NP, Irving S, Jackson ML, Lewin B, Weintraub E. Patterns of childhood immunization and all-cause mortalityexternal icon. Vaccine. 2017 Dec 4; 35(48 Pt B): 6643-6648. Epub 2017 Oct 20.Walter EB, Hornik CP, Grohskopf L, McGee CE, Todd CA, Museru OI, Harrington L, Broder KR. The effect of antipyretics on immune response and fever following receipt of inactivated influenza vaccine in young childrenexternal icon. Vaccine. 2017 Dec 4; 35(48 Pt B): 6664-6671. Epub 2017 Oct 19.VanWormer JJ, Bendixsen CG, Vickers ER, Stokley S, McNeil MM, Gee J, Belongia EA, McLean HQ. Association between parent attitudes and receipt of human papillomavirus vaccine in adolescentsexternal icon. BMC. Public Health. 2017 Oct 2; 17(1): 766.Donahue JG, Kieke BA, King JP, DeStefano F, Mascola MA, Irving SA, Cheetham TC, Glanz JM, Jackson LA, Klein NP, Naleway AL, Weintraub E, Belongia EA. Association of spontaneous abortion with receipt of inactivated influenza vaccine containing H1N1pdm09 in 2010-11 and 2011-12external icon. Vaccine. 2017 Sep 25; 35(40): 5314-5322.Gee J, Sukumaran L, Weintraub E. Risk of Guillain-Barre Syndrome following quadrivalent human papillomavirus vaccine in the Vaccine Safety Datalinkexternal icon. Vaccine. 2017 Oct 13; 35(43): 5756-5758. Epub 2017 Sep 19.Eaton A, Lewis N, Fireman B, Hansen J, Baxter R, Gee J, Klein NP. Birth outcomes following immunization of pregnant women with pandemic H1N1 influenza vaccine 2009-2010external icon. Vaccine. 2017 May 3; 36(19): 2733-2739. Epub 2017 Sep 13.Vickers ER, McClure DL, Naleway AL, Jacobsen SJ, Klein NP, Glanz JM, Weintraub ES, Belongia EA. Risk of venous thromboembolism following influenza vaccination in adults aged 50years and older in the Vaccine Safety Datalinkexternal icon. Vaccine. 2017 Oct 13; 35(43): 5872-5877. Epub 2017 Sep 6.Woo EJ, Moro PL, Cano M, Jankosky C. Postmarketing safety surveillance of trivalent recombinant influenza vaccine: Reports to the Vaccine Adverse Event Reporting System. external iconVaccine. 2017 Oct 9;35(42):5618-5621. Epub 2017 Sep 5.Stockwell MS, Broder KR, Lewis P, Jakob K, Iqbal S, Fernandez N, Sharma D, Barrett A, LaRussa P. Assessing Fever Frequency After Pediatric Live Attenuated Versus Inactivated Influenza Vaccination. external iconJ Pediatric Infect Dis Soc. 2017 Sep 1; 6(3):e7-e14.Shaw J, Halsey NA, Weinberg A, Scott Schmid D, George KS, Weldon WC, Jordan M, Bryant PW, LaRussa P, Bradshaw DY, Harrington T, Gershon A. Arm Paralysis After Routine Childhood Vaccinations: Application of Advanced Molecular Methods to the Causality Assessment of an Adverse Event After Immunizationexternal icon. J Pediatric Infect Dis Soc. 2017 Sep 1; 6(3): e161-e164.Lipkind HS, Vazquez-Benitez G, Nordin JD, Romitti PA, Naleway AL, Klein NP, Hechter RC, Jackson ML, Hambidge SJ, Lee GM, Sukumaran L, Kharbanda EO. Maternal and Infant Outcomes After Human Papillomavirus Vaccination in the Periconceptional Period or During Pregnancyexternal icon. Obstet. Gynecol. 2017 Sep; 130(3): 599-608.Duffy J, Hambidge SJ, Jackson LA, Kharbanda EO, Klein NP, Naleway A, Omer SB, Weintraub E. Febrile Seizure Risk after Vaccination in Children One to Five Months of Ageexternal icon. Pediatr. Neurol. 2017 Nov; 76: 72-78. Epub 2017 Aug 23.Moro PL, Cragan J, Lewis P, Sukumaran L. Major Birth Defects after Vaccination Reported to the Vaccine Adverse Event Reporting System (VAERS) 1990 to 2014external icon. Birth Defects Res. 2017 Jul 17; 109(13): 1057-1062.Heininger U, Holm K, Caplanusi I, Bailey SR, CIOMS Working Group on Vaccine Safety. Guide to active vaccine safety surveillance: Report of CIOMS working group on vaccine safety – executive summaryexternal icon. Vaccine. 2017 Jul 13; 35(32):3917-3921. Epub 2017 Jun 20.DeSilva M, Vazquez-Benitez G, Nordin JD, Lipkind HS, Klein NP, Cheetham TC, Naleway AL, Hambidge SJ, Lee GM, Jackson ML, McCarthy NL, Kharbanda EO. Maternal Tdap vaccination and risk of infant morbidityexternal icon. Vaccine. 2017 Jun 22; 35(29): 3655-3660. Epub 2017 May 25.Duffy J, Johnsen 2, Ferris M, Miller M, Leighton K, McGilvray M, McNamara L, Breakwell L, Yu Y, Bhavsar T, Briere E, Patel M. Safety of a meningococcal group B vaccine used in response to two university outbreaksexternal icon. J Am Coll Health. 2017 Aug-Sep; 65(6):380-388. Epub 2017 May 8.Stockwell MS, Cano M, Jakob K, Broder KR, Gyamfi-Bannerman C, Castaño PM, Lewis P, Barrett A, Museru OI, Castellanos O, LaRussa PS. Feasibility of Text Message Influenza Vaccine Safety Monitoring During Pregnancy. external iconAm J Prev Med. 2017 Sep; 53(3):282-289. Epub 2017 May 8.McLean HQ, VanWormer JJ, Chow BDW, Birchmeier B, Vickers E, DeVries E, Meyer J, Moore J, McNeil MM, Stokley S, Gee J, Belongia EA. Improving Human Papillomavirus Vaccine Use in an Integrated Health System: Impact of a Provider and Staff Interventionexternal icon. J. Adolesc. Health. 2017 Aug; 61(2): 252-258. Epub 2017 Apr 24.Ray GT, Lewis N, Goddard K, Ross P, Duffy J, DeStefano F, Baxter R, Klein NP. Asthma exacerbations among asthmatic children receiving live attenuated versus inactivated influenza vaccinesexternal icon. Vaccine 2017 May 9; 35(20): 2668-2675. Epub 2017 Apr 9.Duffy J, Lewis M, Harrington T, Baxter R, Belongia EA, Jackson LA, Jacobsen SJ, Lee GM, Naleway AL, Nordin J, Daley MF. Live attenuated influenza vaccine use and safety in children and adults with asthmaexternal icon. Ann. Allergy Asthma Immunol. 2017 April; 118(4):439-444.Suragh TA, Miller ER, Hibbs BF, Winiecki SK, Zinderman C, Shimabukuro TT. Cognitive testing to evaluate revisions to the Vaccine Adverse Event Reporting System (VAERS) reporting formexternal icon. Vaccine. 2017 Apr 25; 35(18):2295-2297. Epub 2017 Mar 25.Kharbanda EO, Vazquez-Benitez G, Romitti PA, Naleway AL, Cheetham TC, Lipkind HS, Klein NP, Lee G, Jackson ML, Hambidge SJ, McCarthy N, DeStefano F, Nordin JD. First Trimester Influenza Vaccination and Risks for Major Structural Birth Defects in Offspringexternal icon. J. Pediatr. 2017 Aug; 187: 234-239.e4. Epub 2017 Mar 24.Daley MF, Glanz JM, Newcomer SR, Jackson ML, Groom HC, Lugg MM, McLean HQ, Klein NP, Weintraub ES, McNeil MM. Assessing misclassification of vaccination status: Implications for studies of the safety of the childhood immunization scheduleexternal icon. Vaccine. 2017 Apr 4; 35(15): 1873-1878. Epub 2017 Mar 9.Myers TR, McNeil MM, Ng CS, Li R, Lewis PW, Cano MV. Adverse events following quadrivalent meningococcal CRM-conjugate vaccine (Menveo®) reported to the Vaccine Adverse Event Reporting system (VAERS), 2010-2015external icon. Vaccine. 2017 Mar 27; 35(14):1758-1763. Epub 2017 Mar 3.Klein NP, Lewis E, McDonald J, Fireman B, Naleway A, Glanz J, Jackson LA, Donahue JG, Jacobsen SJ, Weintraub E, Baxter R. Risk factors and familial clustering for fever 7-10days after the first dose of measles vaccines.external iconVaccine. 2017 March 14; 35(12): 1615-1621. Epub 2017 Feb 21.Su JR, Leroy Z, Lewis PW, Haber P, Marin M, Leung J, Woo EJ, Shimabukuro TT. Safety of Second-Dose Single-Antigen Varicella Vaccineexternal icon. Pediatrics. 2017 Mar; 139(3). Epub 2017 Feb 7.Narwaney KJ, Breslin K, Ross CA, Shoup JA, Wain KF, Weintraub ES, McNeil,MM, Hambidge SJ. Vaccine adverse events in a safety net healthcare system and a managed care organizationexternal icon. Vaccine. 2017 March 1; 35(9): 1335-1340. Epub 2017 Feb 6.Moro PL, Sukumaran L. Cholera vaccination: pregnant women excluded no moreexternal icon. Lancet Infect Dis. 2017 May;17(5):469-470. Epub 2017 Feb 2.Hambidge SJ, Ross C, Shoup JA, Wain K, Narwaney K, Breslin K, Weintraub ES, McNeil MM. Integration of data from a safety net health care system into the Vaccine Safety Datalinkexternal icon. Vaccine. 2017 March 1; 35(9): 1329-1334. Epub 2017 Feb 1.Moro P, Baumblatt J, Lewis P, Cragan J, Tepper N, Cano M. Surveillance of Adverse Events After Seasonal Influenza Vaccination in Pregnant Women and Their Infants in the Vaccine Adverse Event Reporting System, July 2010-May 2016external icon. Drug Saf. 2017 Feb; 40(2):145-152.Kharbanda EO, Vazquez-Benitez G, Romitti PA, Naleway AL, Cheetham TC, Lipkind HS, Sivanandam S, Klein NP, Lee GM, Jackson ML, Hambidge SJ, Olsen A, McCarthy N, DeStefano F, Nordin JD. Identifying birth defects in automated data sources in the Vaccine Safety Datalinkexternal icon. Pharmacoepidemiol. Drug Saf. 2017 Apr; 26(4): 412-420. Epub 2017 Jan 4.2016Moro PL, Cragan J, Lewis P, Sukumaran L. Major Birth Defects after Vaccination Reported to the Vaccine Adverse Event Reporting System (VAERS), 1990 to 2014. Birth Defects Res (2017).doi: 10.1002/bdra.23622Moro PL, Sukumaran L. Cholera vaccination: pregnant women excluded no more. Lancet Infect Dis (2017);17(5):469-470. doi: 10.1016/S1473-3099(17)30055-5.Bardenheier BH, Duffy J, Duderstadt SK, Higgs JB, Keith MP, Papadopoulos PJ, Gilliland WR, McNeil MM. Anthrax Vaccine and the Risk of Rheumatoid Arthritis and Systemic Lupus Erythematosus in the U.S. Military: A Case-Control Studyexternal icon. Mil Med. 2016 Oct;181(10):1348-1356.Chen RT, Moro PL, Bauwens J, Bonhoeffer J. Obstetrical and neonatal case definitions for immunization safety data. Vaccine (2016);34(49):5991-5992. doi: 10.1016/j.vaccine.2016.08.026.Moro PL, Woo EJ, Paul W, Lewis P, Petersen BW, Cano M. Post-Marketing Surveillance of Human Rabies Diploid Cell Vaccine (Imovax) in the Vaccine Adverse Event Reporting System (VAERS) in the United States, 1990‒2015. PLoS Negl Trop Dis (2016);10(7):e0004846. doi: 10.1371/journal.pntd.0004846.Moro PL, Li R, Haber P, Weintraub E, Cano M. Surveillance systems and methods for monitoring the post-marketing safety of influenza vaccines at the Centers for Disease Control and Prevention. Expert Opin Drug Saf (2016);15(9):1175-83. doi: 10.1080/14740338.2016.1194823.Moro PL, Cragan J, Tepper N, Zheteyeva Y, Museru O, Lewis P, Broder K. Enhanced surveillance of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccines in pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 2011-2015. Vaccine (2016);34(20):2349-53. doi: 10.1016/j.vaccine.2016.03.049.Lindsey NP, Rabe IB, Miller ER, Fischer M, Staples JE. Adverse event reports following yellow fever vaccination, 2007-13. J Travel Med. 2016 Jul 4;23(5). doi: 10.1093/jtm/taw045Miller ER, Moro PL, Cano M, Lewis P, Bryant-Genevier M, Shimabukuro TT. Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System (VAERS), 1990–2013. Vaccine 2016, 34 (25): 2841-2846. doi: 10.1016/j.vaccine.2016.04.021.Su JR. Miller ER. Duffy J. Baer BM. Cano MV. Notes from the Field:Administration error involving a meningococcal conjugate vaccine-United States, March 1, 2010-Sept. 22, 2015. MMWR 2016 65(06);161-162. doi: 10.15585/mmwr.mm6506a4.Moro, P., Baumblatt, J., Lewis, P. et al. Surveillance of Adverse Events After Seasonal Influenza Vaccination in Pregnant Women and Their Infants in the Vaccine Adverse Event Reporting System, July 2010–May 2016.external iconDrug Saf (2016). doi:10.1007/s40264-016-0482-12015Abrams JY, Weintraub ES, Baggs JM, McCarthy NL, Schonberger LB, Lee GM, et al. Childhood vaccines and Kawasaki disease, Vaccine Safety Datalink, 1996-2006external icon. Vaccine. 2015 Jan 3;33(2):382-7.Baker MA, Kaelber DC, Bar-Shain DS, Moro PL, Zambarano B, Mazza M, et al. Advanced clinical decision support for vaccine adverse event detection and reportingexternal icon. Clin Infect Dis. 2015 Sep 15;61(6):864-70. Epub 2015 Jun 9.Chen RT, Shimabukuro TT, Martin DB, Zuber PL, Weibel DM, Sturkenboom M. Enhancing vaccine safety capacity globally: A lifecycle perspectiveexternal icon. Vaccine. Epub 2015 Sep 30.Chen RT, Shimabukuro TT, Martin DB, et al. Enhancing vaccine safety capacity globally: A lifecycle perspectiveexternal icon. Vaccine. 2015 Nov 27;33 Suppl 4:D46-54.Datwani H, Moro PL, Harrington T, Broder K. Chorioamnionitis following vaccination in the Vaccine Adverse Event Reporting Systemexternal icon. Vaccine. 2015 Jun 17;33(27):3110-3. Epub 2015 May 11.Duffy J, Weintraub E, Vellozzi C, DeStefano F; Vaccine Safety Datalink. Narcolepsy and influenza A(H1N1) pandemic 2009 vaccination in the United Statesexternal icon. Neurology. 2014 Nov 11;83(20):1823-30. Epub 2014 Oct 15.Grohskopf LA, Sokolow LZ, Olsen SJ, Bresee JS, Broder KR, Karron RA. Prevention and control of influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 influenza season. MMWR Morb Mortal Wkly Rep. 2015 Aug 7;64(30):818-25.Haber P, Parashar UD, Haber M, DeStefano F. Intussusception after monovalent rotavirus vaccine—United States, Vaccine Adverse Event Reporting System (VAERS), 2008–2014external icon. Vaccine. 2015 Sep 11;33(38):4873-7. Epub 2015 Aug 11.Hibbs BF, Moro PL, Lewis P, Miller ER, Shimabukuro T. Vaccination errors reported to the Vaccine Adverse Event Reporting System, United States, 2000–2013external icon. Vaccine. 2015 Jun 22;33(28):3171-8. Epub 2015 May 14.Iqbal S, Li R, Gargiullo P, Vellozzi C. Relationship between Guillain-Barré syndrome, influenza-related hospitalizations, and influenza vaccine coverageexternal icon. Vaccine. 2015 Apr 21;33(17):2045-9. Epub 2015 Mar 4.Iqbal S, Shi J, Seib K, Lewis P, Moro PL, Woo EJ, et al. Preparation for global introduction of inactivated poliovirus vaccine: Safety evidence from the US Vaccine Adverse Event Reporting System, 2000-2012external icon. Lancet Infect Dis. 2015 Oct;15(10):1175-82. Epub 2015 Aug 16.Kharbanda EO, Vazquez-Benitez G, Lipkind HS, Klein NP, Cheetham TC, Naleway A, et al. Evaluation of the association of maternal pertussis vaccination with obstetric events and birth outcomesexternal icon. JAMA. 2014 Nov 12;312(18):1897-904.Klein NP, Lewis E, Fireman B, Hambidge SJ, Naleway A, Nelson JC, et al. Safety of measles-containing vaccines in 1-Year-old childrenexternal icon. Pediatrics. 2015 Feb;135(2):e321-9. Epub 2015 Jan 5.Lopalco PL, DeStefano F. The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccinesexternal icon. Vaccine. 2015 Mar 24;33(13):1541-8. Epub 2014 Nov 4.McNamara LA, Shumate AM, Johnsen P, MacNeil JR, Patel M, Bhavsar T, et al. First use of a serogroup B meningococcal vaccine in the us in response to a university outbreakexternal icon. Pediatrics. 2015 May;135(5):798-804.McNeil MM, Weintraub E, Duffy J, Sukumaran L, Jacobsen SJ, Klein NP, et al. Risk of anaphylaxis following vaccination in children and adultsexternal icon. J Allergy Clin Immunol. Epub 2015 Sep 28.Miller ER, Moro PL, Cano M, Shimabukuro T. Deaths following vaccination: What does the evidence show?external iconVaccine. 2015 Jun 26;33(29):3288-92. Epub 2015 May 23.Miller ER, Shimabukuro T, Hibbs B, Moro P, Broder K, Vellozzi C. Vaccine safety resources for nursesexternal icon. Am J Nurs. 2015 Aug; 115(8):55-58.Moro PL, Arana J, Cano M, Lewis P, Shimabukuro TT. Deaths reported to the Vaccine Adverse Event Reporting System, United States, 1997-2013external icon. Clin Infect Dis. 2015 Sep 15;61(6):980-7. Epub 2015 May 28.Moro PL, Jankosky C, Menschik D, Lewis P, Duffy J, Stewart B, et al. Adverse events following Haemophilus influenzae type b vaccines in the Vaccine Adverse Event Reporting System, 1990-2013external icon. J Pediatr. 2015 Apr;166(4):992-7. Epub 2015 Jan 15.Moro PL, McNeil MM, Sukumaran L, Broder KR. The Centers for Disease Control and Prevention’s public health response to monitoring Tdap safety in pregnant women in the United Statesexternal icon. Hum Vaccin Immunother. Epub 2015 Sep 17.Moro PL, Zheteyeva Y, Lewis P, Shi J, Yue X, Museru OI, et al. Safety of quadrivalent human papillomavirus vaccine (Gardasil®) in pregnancy: Adverse events among non-manufacturer reports in the Vaccine Adverse Event Reporting System, 2006-2013.external iconVaccine. 2015 Jan; 33(4): 519-22.Payne DC, Baggs J, Klein NP, Parashar UD. Does preventing rotavirus infections through vaccination also protect against naturally occurring intussusception over time?external iconClin Infect Dis. 2015 Jan 1;60(1):163-4.Petrosky E, Bocchini JA Jr, Hariri S, Chesson H, Curtis CR, Saraiya M, et al; Centers for Disease Control and Prevention (CDC). Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015 Mar 27;64(11):300-4.Rabe IB, Miller ER., Fischer M, Hills SL. Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009-2012external icon. Vaccine. 2015 Jan 29;33(5):708-12.Rha B, Tate JE, Weintraub E, Haber P, Yen C, Patel M, Cortese MM. Intussusception following rotavirus vaccination: An updated review of the available evidenceexternal icon. Expert Rev Vaccines. 2014 Nov;13(11):1339-48. Epub 2014 Jul 26.Stratton KG, Cook AJ, Jackson LA, Nelson JC. Simulation study comparing exposure matching with regression adjustment in an observational safety setting with group sequential monitoringexternal icon. Stat Med. 2015 Mar 30;34(7):1117-33.Shimabukuro TT, Nguyen M, Martin D, DeStefano F. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)external icon. Vaccine. 2015 Aug 26;33(36):4398-405. Epub 2015 Jul 22.Sukumaran L, McCarthy NL, Kharbanda EO, McNeil MM, Naleway AL, Klein NP, et al. Association of Tdap vaccination with acute events and adverse birth outcomes among pregnant women with prior tetanus-containing immunizationsexternal icon. JAMA. 2015 Oct 20;314(15):1581-1587.Sukumaran L, McCarthy NL, Kharbanda EO, Weintraub ES, Vasquez-Benitez G, McNeil MM, et al. Safety of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis and influenza vaccinations in pregnancy.external iconObstet Gynecol. 2015 Nov;126(5):1069-74.Sukumaran L, McCarthy NL, Li R, Weintraub ES, Jacobsen SJ, Hambidge SJ, et al. Demographic characteristics of members of the Vaccine Safety Datalink (VSD): A comparison with the United States populationexternal icon. Vaccine. 2015 Aug 26;33(36):4446-50. Epub 2015 Jul 23.Sukumaran L, McNeil MM, Moro PL, Lewis PW, Winiecki SK, Shimabukuro TT. Adverse events following measles, mumps, and rubella vaccine in adults reported to the Vaccine Adverse Event Reporting System (VAERS), 2003-2013.external iconClin Infect Dis. 2015 May 15;60(10):e58-65.2014Briere EC, Rubin L, Moro PL, Cohn A, Clark T, Messonnier N. Prevention and control of haemophilus influenzae type b disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2014 Feb 28;63(RR-01):1-14Daley MF, Yih WK, Glanz JM, Hambidge SJ, Narwaney KJ, Yin R, et al. Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP-IPV) vaccineexternal icon. Vaccine. 2014;32(25):3019-3024.Duffy J, Weintraub, E, Vellozzi, C, DeStefano F. Narcolepsy and influenza A(H1N1) pandemic 2009 vaccination in the United Statesexternal icon. Neurology. 2014;83(20):1823-30.Grohskopf LA, Olsen SJ, Sokolow LZ, Bresee JS, Cox NJ, et al. Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP) — United States, 2014–15 influenza season. MMWR. 2014 Aug 15;63(32):691-697.Haber P, Moro PL, McNeil MM, Lewis P, Woo EJ, Hughes H, Shimabukuro TT. Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013external icon. Vaccine. 2014 Nov;32(48):6499-504.Haber P, Moro PL, McNeil MM, Lewis P, Woo EJ, Hughes H, et al. Post-licensure surveillance of trivalent live attenuated influenza vaccine in children aged 2-18 years, Vaccine Adverse Event Reporting System (VAERS), United States, July 2005-June 2012external icon. J Ped Infect Dis. Epub 2014 May 7.Hambidge SJ, Newcomer SR, Narwaney KJ, Glanz JM, Daley MF, Xu S, et al. Timely versus delayed early childhood vaccination and seizures.external iconPediatrics. 2014 Jun;133(6):e1492-9.Hibbs BF, Miller ER, Shimabukuro T; Centers for Disease Control and Prevention (CDC). Notes from the field: Rotavirus vaccine administration errors–United States, 2006-2013external icon. MMWR. 2014 Jan;63(4):81.Hofstetter AM, Jakob K, Klein NP, Dekker CL, Edwards KM, et al. Live vaccine use and safety in DiGeorge syndromeexternal icon. Pediatrics. 2014 Apr;133(4):e946-54.Jackson ML, Peterson D, Nelson JC, Greene SK, Jacobsen SJ, Belongia EA, et al. Using winter 2009-2010 to assess the accuracy of methods which estimate influenza-related morbidity and mortalityexternal icon. Epidemiol Infect. 2014 Dec 12:1-9.Kawai AT, Li L, Kulldorff M, Vellozzi C, Weintraub E, Baxter R, et al. Absence of associations between influenza vaccines and increased risks of seizures, Guillain-Barre syndrome, encephalitis, or anaphylaxis in the 2012-2013 seasonexternal icon. Pharmacoepidemiol Drug Saf. 2014;23(5):548-553.Kharbanda EO, Vazquez-Benitez G, Lipkind HS, Klein NP, Cheetham TC, Naleway A, et al. Evaluation of the association of maternal pertussis vaccination with obstetric events and birth outcomes.external iconJAMA. 2014 Nov;312(18):1897-904.Kharbanda EO, Vazquez-Benitez G, Lipkind H, Naleway AL, Klein NP, Cheetham TC, et al. Receipt of pertussis vaccine during pregnancy across 7 Vaccine Safety Datalink sitesexternal icon. Prev Med. 2014 Oct;67:316-9.Li R, Stewart B, Weintraub E, McNeil MM. Continuous sequential boundaries for vaccine safety surveillanceexternal icon. Stat Med. 2014 Aug 30;33(19):3387-3397.Lopalco PL, DeStefano F. The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccinesexternal icon. Vaccine. 2015 Mar 24;33(13):1541-8.McNeil MM, Cano M, Miller ER, Petersen BW, Engler RJ, Bryant-Genevier MG. Ischemic cardiac events and other adverse events following ACAM2000® smallpox vaccine in the Vaccine Adverse Event Reporting Systemexternal icon. Vaccine. 2014 Aug 20;32(37):4758-65.McNeil MM, Gee J, Weintraub ES, Belongia EA, Lee GM, Glanz JM, et al. The Vaccine Safety Datalink: Successes and challenges monitoring vaccine safetyexternal icon. Vaccine. 2014 Sep 22;32(42):5390-5398.Moro PL, Museru OI, Niu M, Lewis P, Broder K. Reports to the Vaccine Adverse Event Reporting System after hepatitis A and hepatitis AB vaccines in pregnant womenexternal icon. Am J Obstet Gynecol. 2014 Jun;210(6):561.e1-6Naleway AL, Irving SA, Henninger ML, Li DK, Shifflett P, Ball S, et al. Safety of influenza vaccination during pregnancy: A review of subsequent maternal obstetric events and findings from two recent cohort studiesexternal icon. Vaccine. 2014;32(26):3122-3127.Naleway AL, Kurosky S, Henninger ML, Gold R, Nordin JD, Kharbanda EO, et al. Vaccinations given during pregnancy, 2002-2009: a descriptive studyexternal icon. Am J Prev Med. 2014;46(2):150-157.Nelson JC, Shortreed SM, Yu O, Peterson D, Baxter R, Fireman B, et al. Integrating database knowledge and epidemiological design to improve the implementation of data mining methods to evaluate vaccine safety in large healthcare databasesexternal icon. Stat Anal Data Min. 2014 Oct;7(5):337–351.Nordin JD, Kharbanda EO, Vazquez-Benitez G, Lipkind H, Lee GM, Naleway AL. Monovalent H1N1 influenza vaccine safety in pregnant women, risks for acute adverse eventsexternal icon. Vaccine. 2014 Sep 3;32(39):4985-4992.Nordin JD, Kharbanda EO, Vazquez Benitez G, Lipkind H, Vellozzi C, Destefano F; Vaccine Safety Datalink. Maternal influenza vaccine and risks for preterm or small for gestational age birth.external iconJ Pediatr. 2014 May;164(5):1051-1057.e2.Stockwell MS, Broder K, LaRussa P, Lewis P, Fernandez N, Sharma D, et al. Risk of fever after pediatric trivalent inactivated influenza vaccine and 13-valent pneumococcal conjugate vaccine.external iconJAMA Pediatr. 2014 Mar;168(3):211-9.Tartof SY, Tseng HF, Liu IL, Qian L, Sy LS, Hechter RC, et al. Inpatient admission for febrile seizure and subsequent outcomes do not differ in children with vaccine-associated versus non-vaccine associated febrile seizuresexternal icon. Vaccine. 2014;32(48):6408-14.Tartof SY, Tseng HF, Liu AL, Qian L, Sy LS, Hechter RC, et al. Exploring the risk factors for vaccine-associated and non-vaccine associated febrile seizures in a large pediatric cohortexternal icon. Vaccine. 2014;32(22):2574-2581Weintraub ES, Baggs J, Duffy J, Vellozzi C, Belongia EA, Irving S, et al. Risk of intussusception after monovalent rotavirus vaccinationexternal icon. N Engl J Med. 2014 Feb; 370:513-519.Xu S, Newcomer S, Nelson J, Qian L, McClure D, Pan Y, et al. Signal detection of adverse events with imperfect confirmation rates in vaccine safety studies using self-controlled case series designexternal icon. Biom J. 2014 May;56(3):513-25.2013Baxter R, Bakshi N, Fireman B, Lewis E, Ray P, Vellozzi C, et al. Lack of association of Guillain-Barre syndrome with vaccinationsexternal icon. Clin Infect Dis. 2013 Jul;57(2):197-204.DeStefano F, Price CS, Weintraub ES. Increasing exposure to antibody-stimulating proteins and polysaccharides in vaccines Is not associated with risk of autismexternal icon. J Pediatr. 2013 Aug;163(2):561-7.Dodd CN, Romio SA, Black S, Vellozzi C, Andrews N, Sturkenboom M, et al. International collaboration to assess the risk of Guillain Barré Syndrome following influenza A (H1N1) 2009 monovalent vaccinesexternal icon. Vaccine. 2013 Sep;31(40):4448-58.Glanz JM, Narwaney KJ, Newcomer SR, Daley MF, Hambidge SJ, Rowhani-Rahbar A, et al. Association between undervaccination with Diphtheria. Tetanus Toxoids, and Acellular Pertussis (DTaP) vaccine and risk of pertussis infection in children 3 to 36 months of age.external iconJAMA Pediatr. 2013 Nov;167(11):1060-4.Glanz JM, Newcomer SR, Narwaney KJ, Hambidge SJ, Daley MF, Wagner NM, et al. A population-based cohort study of undervaccination in 8 managed care organizations across the United Statesexternal icon. JAMA Pediatr. 2013;167(3):274-281.Gold R, Naleway A, Riedlinger K. Factors predicting completion of the human papillomavirus vaccine seriesexternal icon. J Adolesc Health. 2013;52(4):427-432.Greene SK, Li L, Shay DK, Fry AM, Lee GM, Jacobsen SJ, et al. Risk of adverse events following oseltamivir treatment in influenza outpatients, Vaccine Safety Datalink Project, 2007-2010external icon. Pharmacoepidemiol Drug Saf. 2013;22(4):335-344.Greene SK, Rett MD, Vellozzi C, Li L, Kulldorff M, Marcy SM, et al. Guillain-Barré syndrome, influenza vaccination, and antecedent respiratory and gastrointestinal infections: A case-centered analysis in the Vaccine Safety Datalink, 2009-2011external icon. PLoS One. 2013 Jun;8(6):e67185.Haber P, Patel M, Pan Y, Baggs J, Haber M, Museru O, et al. Intussusception after Rotavirus Vaccines—United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2012external icon. Pediatrics. 2013 Jun;131(6):1042-9.Halsey NA, Griffioen M, Dreskin SC, Dekker CL, Wood R, Sharma D, et al. Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: Reports to VAERS.external iconVaccine. 2013 Dec;31(51):6107-12.Hechter RC, Qian L, Sy LS, Greene SK, Weintraub ES, Naleway AL, et al. Secular trends in diagnostic code density in electronic healthcare data from health care systems in the Vaccine Safety Datalink Projectexternal icon. Vaccine. 2013 Feb;31(7):1080-85.Henninger M, Crane B, Naleway A. Trends in influenza vaccine coverage in pregnant women, 2008 to 2012external icon. Perm J. 2013;17(2):31-36.Henninger M, Naleway A, Crane B, Donahue J, Irving S. Predictors of seasonal influenza vaccination during pregnancyexternal icon. Obstet Gynecol. 2013;121(4):741-749.Iqbal S, Barile JP, Thompson WW, DeStefano F. Number of antigens in early childhood vaccines and neuropsychological outcomes at age 7-10 yearsexternal icon. Pharmacoepidemiol Drug Saf. 2013;22(12):1263-1270.Irving SA, Kieke BA, Donahue JG, Mascola MA, Baggs J, DeStefano F, et al. Trivalent inactivated influenza vaccine and spontaneous abortionexternal icon. Obstet Gynecol. 2013;121(1):159-165.Jackson ML, Yu O, Nelson JC, Naleway A, Belongia EA, Baxter R, et al. Further evidence for bias in observational studies of influenza vaccine effectiveness: the 2009 influenza A(H1N1) pandemicexternal icon. Am J Epidemiol. 2013;178(8):1327-1336.Jackson LA, Peterson D, Nelson JC, Marcy SM, Naleway AL, Nordin JD, et al. Vaccination site and risk of local reactions in children 1 through 6 years of ageexternal icon. Pediatrics. 2013 Feb;131(2):283-9.Kharbanda EO, Vazquez-Benitez G, Lipkind H, Naleway A, Lee G, Nordin JD; Vaccine Safety Datalink. Inactivated influenza vaccine during pregnancy and risks for adverse obstetric events.external iconObstet Gynecol. 2013 Sep;122(3):659-67.Kharbanda EO, Vazquez-Benitez G, Shi WX, Lipkind H, Naleway A, Molitor B, et al. Assessing the safety of influenza immunization during pregnancy: the Vaccine Safety Datalinkexternal icon. Am J Obstet Gynecol. 2012;207(3 Suppl):S47-S51.McCarthy NL, Gee J, Lin ND, Thyagarajan V, Pan Y, Su S, et al. Evaluating the safety of influenza vaccine using a claims-based health systemexternal icon. Vaccine. 2013 Dec;31(50):5975-82.McCarthy NL, Weintraub E, Vellozzi C, Duffy J, Gee J, Donahue JG, et al. Mortality rates and cause-of-death patterns in a vaccinated populationexternal icon. Am J Prev Med. 2013 Jul;45(1):91-7.McCarthy NL, Irving S, Donahue JG, Weintraub E, Gee J, Belongia E, et al. Vaccination coverage levels among children enrolled in the Vaccine Safety Datalink.external iconVaccine. 2013 Dec;31(49):5822.McNeil MM, Li R, Pickering S, Real TM, Smith PJ, Pemberton MR, et al. Who is unlikely to report adverse events after vaccinations to the Vaccine Adverse Event Reporting System (VAERS)?external iconVaccine. 2013 May;31(24):2673-9. 2013 Apr.Moro PL, Harrington T, Shimabukuro T, Cano M, Museru OI, Menschik D, et al. Adverse events after Fluzone® Intradermal vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2011-2013external icon. Vaccine. 2013 Oct;31(43):4984-7.Moro PL, Museru OI, Broder K, Cragan J, Zheteyeva Y, Tepper N, et al. Safety of influenza A (H1N1) 2009 live attenuated monovalent vaccine in pregnant womenexternal icon. Obstet Gynecol. 2013 Dec;122(6):1271-8.Naleway AL, Gold R, Kurosky S, Riedlinger K, Henninger ML, Nordin JD, et al. Identifying pregnancy episodes, outcomes, and mother-infant pairs in the Vaccine Safety Datalinkexternal icon. Vaccine. 2013;31(27):2898-2903.Nelson JC, Yu O, Dominguez-Islas CP, Cook AJ, Peterson D, Greene SK, et al. Adapting group sequential methods to observational postlicensure vaccine safety surveillance: Results of a pentavalent combination DTaP-IPV-Hib vaccine safety studyexternal icon. Am J Epidemiol. 2013 Jan;177(2):131-41.Nelson JC, Marsh T, Lumley T, Larson EB, Jackson LA, Jackson M, et al. Validation sampling can reduce bias in health care database studies: an illustration using influenza vaccination effectivenessexternal icon. J Clin Epidemiol. 2013;66(8 Suppl):S110-S121.Newcomer SR, Hambidge SJ, McClure DL, Daley MF, Klein NP, Glanz JM. Factors that may explain observed associations between trivalent influenza vaccination and gastrointestinal illness in young childrenexternal icon. Vaccine. 2013;31(37):3894-3898.Nordin JD, Parker ED, Vazquez-Benitez G, Kharbanda EO, Naleway A, Marcy SM, et al. Safety of the yellow fever vaccine: a retrospective studyexternal icon. J Travel Med. 2013;20(6):368-373.Nordin JD, Kharbanda EO, Benitez GV, Nichol K, Lipkind H, Naleway A, et al. Maternal safety of trivalent inactivated influenza vaccine in pregnant women.external iconObstet Gynecol. 2013 Mar;121(3):519-25.Pahud BA, Williams SE, Dekker CL, Halsey N, LaRussa P, et al. Clinical assessment of serious adverse events in children receiving 2009 H1N1 vaccinationexternal icon. Pediatr Infect Dis J. 2013 Feb;32(2):163-168.Pan Y, Rose CE, Haber M, Ma Y, Carrasco JL, Stewart B, et al. Assessing agreement of repeated binary measurements with an application to the CDC’s anthrax vaccine clinical trialexternal icon. Int J Biostat. 2013 Jul;9(1). 14.Poli F, Overeem S, Lammers GJ, et al. Narcolepsy as an adverse event following immunization: case definition and guidelines for data collection, analysis and presentationexternal icon. Vaccine. 2013 Jan 30;31(6):994-1007.Qian L, Tseng HF, Sy LS, Jacobsen SJ. Confounder adjustment in vaccine safety studies: Comparing three offset terms for case-centered approachexternal icon. Vaccine. 2013 Jan;31(2):431-5.Rowhani-Rahbar A, Fireman B, Lewis E, Nordin J, Naleway A, Jacobsen SJ, et al. Effect of age on the risk of fever and seizures following immunization with measles-containing vaccines in childrenexternal icon. JAMA Pediatr. 2013 Dec;167(12):1111-7.Salmon DA, Proschan M, Forshee R, Gargiullo P, Bleser W, Burwen DR, et al. Association between Guillain-Barre syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysisexternal icon. Lancet. 2013;381(9876):1461-1468.Schmidt MA, Gold R, Kurosky SK, Daley MF, Irving SA, Gee J, et al. Uptake, coverage, and completion of quadrivalent human papillomavirus vaccine in the Vaccine Safety Datalink, July 2006-June 2011.external iconJ Adolesc Health. 2013 Nov;53(5):637-41.Thyagarajan V, Su S, Gee J, Duffy J, McCarthy NL, Chan KA, et al. Identification of seizures among adults and children following influenza vaccination using health insurance claims data.external iconVaccine. 2013 Dec;31(50):5997-6002.Tseng HF, Sy LS, Qian L, Marcy SM, Jackson LA, Glanz J, et al; Vaccine Safety Datalink. Safety of a tetanus-diphtheria-acellular pertussis vaccine when used off-label in an elderly population.external iconClin Infect Dis. 2013 Feb;56(3):315-21.Williams SE, Edwards KM, Baxter RP, Larussa PS, Halsey NA, et al. Comprehensive assessment of serious adverse events following immunization by health care providersexternal icon. J Pediatr. 2013 Jun;162(6):1276-81, 1281.e1.Xu S, Hambidge SJ, McClure DL, Daley MF, Glanz JM, et al. A scan statistic for identifying optimal risk windows in vaccine safety studies using self-controlled case series designexternal icon. Stat Med. 2013;30;32(19):3290-9.Zeng C, Newcomer SR, Glanz JM, Shoup JA, Daley MF, Hambidge SJ, et al. Bias correction of risk estimates in vaccine safety studies with rare adverse events using a self-controlled case series designexternal icon. Am J Epidemiol.2013;178(12):1750-1759.Zheteyeva Y, Moro PL, Yue X, Broder K. Safety of meningococcal polysaccharide-protein conjugate vaccine in pregnancy: a review of the Vaccine Adverse Event Reporting System.external iconAm J Obstet Gynecol. 2013 Aug;208(6):478.e1-6.2012Baxter R, Lewis N, Bakshi N, Vellozzi C, Klein NP; CISA Network. Recurrent Guillain-Barre syndrome following vaccinationexternal icon. Clin Infect Dis. 2012 Mar;54(6):800-4.Broder KR, Martin DB, Vellozzi C. In the heat of a signal: Responding to a vaccine safety signal for febrile seizures after 2010–11 influenza vaccine in young children, United States.external iconVaccine. 2012 Mar;30(11):2032-34.Cano M, Lewis P, Ou AC, Sharma D, Vellozzi C, Broder KR. Bell’s palsy cases following administration of influenza A (H1N1) 2009 monovalent vaccine reported to the Vaccine Adverse Event Reporting System (VAERS)[PDF – 1.84 MB].external iconJ Vaccines Vaccin. 2012;3(2)134.Greene SK, Rett M, Weintraub ES, Li L, Yin R, Amato AA, et al. Risk of confirmed Guillain-Barre syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the Vaccine Safety Datalink project, 2009-2010external icon. Am J Epidemiol. 2012;175(11):1100-1109.Greene SK, Shay DK, Yin R, McCarthy NL, Baxter R, Jackson ML, et al. Patterns in influenza antiviral medication use before and during the 2009 H1N1 pandemic, Vaccine Safety Datalink Project, 2000-2010external icon. Influenza Other Respir Viruses.2012;6(6):e143-e151.Halsey NA, Edwards KM, Dekker CL, Klein NP, Baxter R, et al. Algorithm to assess causality after individual adverse events following immunizationsexternal icon. Vaccine. 2012 Aug 24;30(39):5791-8.Hambidge SJ, Ross C, Glanz J, McClure D, Daley MF, Xu S, et al. Trivalent inactivated influenza vaccine is not associated with sickle cell crises in childrenexternal icon. Pediatrics. 2012;129(1):e54-e59.Hechter RC, Qian L, Sy LS, Greene SK, Weintraub ES, Naleway AL, et al. Secular trends in diagnostic code density in electronic healthcare data from health care systems in the Vaccine Safety Datalink projectexternal icon. Vaccine. 2012;31(7):1080-1085.Klein NP, Lewis E, Baxter R, Weintraub E, Glanz J, Naleway A, et al. Measles-containing vaccines and febrile seizures in children age 4 to 6 yearsexternal icon. Pediatrics. 2012;129(5):809-814.Leroy Z, Broder K, Menschik D, Shimabukuro T, Martin D. Febrile seizures after 2010–2011 influenza vaccine in young children, United States: A vaccine safety signal from the vaccine adverse event reporting systemexternal icon. Vaccine. 2012;30(11):2020-3.Loughlin AM, Marchant CD, Adams W, Barnett E, Baxter R, et al. Causality assessment of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS)external icon. Vaccine. 2012 Nov 26;30(50):7253-9.McClure DL, Xu S, Weintraub E, Glanz JM. An efficient statistical algorithm for a temporal scan statistic applied to vaccine safety analysesexternal icon. Vaccine. 2012;30(27):3986-3991.Moro PL, Tepper NK, Grohskopf LA, Vellozzi C, Broder K. Safety of seasonal influenza and influenza A (H1N1) 2009 monovalent vaccines in pregnancy.external iconExpert Rev Vaccines. 2012 Aug;11(8):911-21.Moro PL, Arana J, Cano M, Menschik D, Yue Lewis P, Haber P, et al. Postlicensure safety surveillance for high-dose trivalent inactivated influenza vaccine in the Vaccine Adverse Event Reporting System, 1 July 2010–31 December 2010external icon. Clin Infect Dis. 2012;54(11):1608-14.Naleway AL, Gold R, Drew L, Riedlinger K, Henninger ML, Gee J. Reported adverse events in young women following quadrivalent human papillomavirus vaccinationexternal icon. J Womens Health (Larchmt.). 2012;21(4):425-432.Pahud BA, Rowhani-Rahbar A, Glaser C, Gavali S, Salibay CJ, et al. Lack of association between childhood immunizations and encephalitis in California, 1998-2008external icon. Vaccine. 2012 Jan 5;30(2):247-53.Rowhani-Rahbar A, Baxter R, Rasgon B, Ray P, Black S, Klein JO, et al. Epidemiologic and clinical features of Bell’s palsy among children in northern Californiaexternal icon. Neuroepidemiology. 2012;38(4):252-258.Rowhani-Rahbar A, Fireman B, Lewis N, Ray P, Rasgon B, Klein JO, et al. Rowhani-Rahbar et al. respond to “Immunization and Bell’s palsy in children.”external iconAm J Epidemiol. 2012;175(9):888-889.Rowhani-Rahbar A, Klein NP, Dekker CL, Edwards KM, Marchant CD, et al. Biologically plausible and evidence-based risk intervals in immunization safety researchexternal icon. Vaccine. 2012 Dec 17;31(1):271-7.Rowhani-Rahbar A, Klein NP, Lewis N, Fireman B, Ray P, Rasgon B, et al. Immunization and Bell’s palsy in children: a case-centered analysisexternal icon. Am J Epidemiol. 2012;175(9):878-885.Shui IM, Baggs J, Patel M, Parashar UD, Rett M, Belongia EA, et al. Risk of intussusception following administration of a pentavalent rotavirus vaccine in US infantsexternal icon. JAMA. 2012;307(6):598-604.Shui IM, Rett MD, Weintraub E, Marcy M, Amato AA, Sheikh SI, et al. Guillain-Barré syndrome incidence in a large United States cohort (2000-2009)external icon. Neuroepidemiology. 2012;39(2):109-115.Stewart B, Rose CE, Tokars JI, Martin SW, Keitel WA, Keyserling HL, et al. Health-related quality of life in the CDC Anthrax Vaccine Adsorbed Human Clinical Trial.external iconVaccine. 2012 Aug;30(40):5875-9.Tokars JI, Lewis P, DeStefano F, Wise M, Viray M, Morgan O, Gargiullo P, Vellozzi C. The risk of Guillain-Barré syndrome associated with influenza A (H1N1) 2009 monovalent vaccine and 2009-2010 seasonal influenza vaccines: results from self-controlled analysesexternal icon. Pharmacoepidemiol Drug Saf. 2012 May;21(5):546-52.Tse A, Tseng HF, Greene SK, Vellozzi C, Lee GM, VSD Rapid Cycle Analysis Influenza Working Group. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011external icon. Vaccine. 2012;30(11):2024-2031.Tseng HF, Sy LS, Qian L, Marcy SM, Jackson LA, Glanz J, et al; Vaccine Safety Datalink. Safety of a tetanus-diphtheria-acellular pertussis vaccine when used off-label in an elderly population.external iconClin Infect Dis. 2013 Feb;56(3):315-21.Wise ME, Viray M, Sejvar JJ, Lewis P, Baughman AL, Connor W, Danila R, Giambrone GP, Hale C, Hogan BC, Meek JI, Murphree R, Oh JY, Reingold A, Tellman N, Conner SM, Singleton JA, Lu PJ, DeStefano F, Fridkin SK, Vellozzi C, Morgan OW. Guillain-Barre syndrome during the 2009-2010 H1N1 influenza vaccination campaign: population-based surveillance among 45 million Americansexternal icon. Am J Epidemiol. 2012 Jun 1;175(11):1110-9.Xu S, Zeng C, Newcomer S, Nelson J, Glanz J. Use of fixed effects models to analyze self-controlled case series data in vaccine safety studiesexternal icon. J Biom Biostat. 2012;Suppl 7:006.Yih WK, Weintraub E, Kulldorff M. No risk of Guillain-Barré syndrome found after meningococcal conjugate vaccination in two large cohort studiesexternal icon. Pharmacoepidemiol Drug Saf. 2012;21(12):1359-1360.Zheteyeva YA, Moro PL, Tepper NK, Rasmussen SA, Barash FE, Revzina NV, et al. Adverse event reports after tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines in pregnant womenexternal icon. Am J Obstet Gynecol. 2012 Jul; 207(1):59.e1-7.2011Baggs J, Gee J, Lewis E, Fowler G, Benson P, Lieu T, et al. The Vaccine Safety Datalink: A model for monitoring immunization safety.external iconPediatrics. 2011 May;127 Suppl 1:S45-53.Barile JP, Kuperminc GP, Weintraub ES, Mink JW, Thompson WW, et al. Thimerosal exposure in early life and neuropsychological outcomes 7-10 years laterexternal icon. J Pediatr Psychol. 2011;37(1):106-118.Gee J, Naleway A, Shui I, Baggs J, Yin R, Li R, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink.external iconVaccine. 2011 Oct; 29(46):8279-84.Gidudu J, Sack DA, Pina M, Hudson MJ, Kohl KS, Bishop P, et al. Diarrhea: Case definition and guidelines for collection, analysis, and presentation of immunization safety data.external iconVaccine. 2011 Jan;29(5): 1053-71.Glanz JM, Newcomer SR, Hambidge SJ, Daley MF, Narwaney KJ, Xu S, et al. Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the Vaccine Safety Datalinkexternal icon. Arch Pediatr Adolesc Med.2011;165(8):749-755.Greene SK, Kulldorff M, Yin R, Yih WK, Lieu TA, Weintraub ES, et al. Near real-time vaccine safety surveillance with partially accrued data.external iconPharmacoepidemiol Drug Saf. 2011 Jun;20(6):583-90Haber P, Iskander J, Walton K, Campbell SR, Kohl KS., et al. Internet-based reporting to the vaccine adverse event reporting system: a more timely and complete way for providers to support vaccine safetyexternal icon. Pediatrics. 2011 May;127 Suppl 1: S39-44.Hambidge SJ, Ross C, McClure D, Glanz J; VSD team. Trivalent inactivated influenza vaccine is not associated with sickle cell hospitalizations in adults from a large cohortexternal icon. Vaccine. 2011;29(46):8179-8181.Huang WT, Suh C, Campagna E, Broder KR, Daley MF, Crane LA, et al. Adherence to the advisory committee on immunization practices recommendation to prevent injuries from postvaccination syncope: A national physician surveyexternal icon. Am J Prev Med. 2011 Sep;41(3):317-21.Jackson LA, Yu O, Nelson JC, Dominguez C, Peterson D, Baxter R, et al. Injection site and risk of medically attended local reactions to acellular pertussis vaccineexternal icon. Pediatrics. 2011;127(3):e581-e587.Jackson LA, Peterson D, Dunn J, Hambidge SJ, Dunstan M, Starkovichet P. A randomized placebo-controlled trial of acetaminophen for prevention of post-vaccination fever in infantsexternal icon. PLoS One. 2011;6(6):e20102.Klein NP, Aukes L, Lee J, Fireman B, Shapira SK, Slade B, et al. Evaluation of immunization rates and safety among children with inborn errors of metabolism.external iconPediatrics. 2011 May;127(5):e1139-46.Klein NP, Gidudu J, Qiang Y, Pahud B, Rowhani-Rahbar A, Baxter R, et al. Developing the next generation of vaccinologists.external iconVaccine. 2011 Nov;29(50):9296-97.Kulldorff M, Davis RL, Kolczak M, Lewis E, Lieu T, Platt R. A maximized sequential probability ratio test for drug and vaccine safety surveillance.external iconSeq Anal. 2011 Jan;30(1): 58-78.LaRussa PS, Edwards KM, Dekker CL, Klein NP, Halsey NA, Marchant C, et al. Understanding the role of human variation in vaccine adverse events: The Clinical Immunization Safety Assessment Network.external iconPediatrics. 2011 May;127 Suppl 1:S65-73.Lee GM, Greene SK, Weintraub ES, Baggs J, Kulldorff M, Fireman BH. H1N1 and seasonal influenza vaccine safety in the Vaccine Safety Datalink projectexternal icon. Am J Prev Med. 2011;41(2):121-128.McCarthy NL, Gee J, Weintraub E, Donahue JG, Nordin JD, Daley MF, et al. Monitoring vaccine safety using the Vaccine Safety Datalink: Utilizing immunization registries for pandemic influenza.external iconVaccine. 2011 Jul; 29(31):4891-96.Miller EK, Batten B, Hampton L, Campbell SR, Gao J, Iskander J. Tracking vaccine-safety inquiries to detect signals and monitor public concerns.external iconPediatrics. 2011 May;127 Suppl 1:S87-91.Miller EK, Dumitrescu L, Cupp C, Dorris S, Taylor S, Sparks R. Atopy history and the genomics of wheezing after influenza vaccination in children 6-59 months of age.external iconVaccine. 2011 Apr;29(18):3431-37.Morgan TM, Schlegel C, Edwards KM, Welch-Burke T, Zhu Y, Sparks R. Vaccines are not associated with metabolic events in children with urea cycle disorders.external iconPediatrics. 2011 May;127(5):e1147-53.Moro PL, Broder K, Zheteyeva Y, Revzina N, Tepper N, Kissin D, et al. Adverse events following administration to pregnant women of influenza A (H1N1) 2009 monovalent vaccine reported to the Vaccine Adverse Event Reporting Systemexternal icon. Am J Obstet Gynecol. 2011; 205(5):473.e1-9.Moro PL, Yue X, Lewis P, Haber P, Broder K. Adverse events after tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine administered to adults 65 years of age and older reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2010external icon. Vaccine. 2011;29(50):9404-8.Moro PL, Broder K, Zheteyeva Y, Walton K, Rohan P, Sutherland A, et al. Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the Vaccine Adverse Event Reporting System, 1990-2009external icon. Am J Obstet Gynecol. 2011 Feb; 204(2):146.e1-7.Mullooly JP, Schuler R, Mesa J, Drew L, DeStefano F; VSD team. Wheezing lower respiratory disease and vaccination of premature infantsexternal icon. Vaccine. 2011;29(44):7611-7617.Navar-Boggan AM, Halsey NA, Escobar GJ, Golden WC, Klein NP. Underimmunization in the Neonatal Intensive Care Unitexternal icon. J Perinatol. 2012 May;32(5):363-7.Nelson JC, Cook AJ, Yu O, et al. Methods for observational post-licensure medical product safety surveillanceexternal icon. Stat Methods Med Res. Epub 2 Dec 2011.Nordin JD, Yih WK, Kulldorff M, Weintraub E. Tdap and GBS letterexternal icon. Vaccine. 2011 Feb;29(6):1122.Pahud BA, Glaser CA, Dekker CL, Arvin AM, Schmid DS. Varicella zoster disease of the central nervous system: Epidemiological, clinical, and laboratory features 10 years after the introduction of the varicella vaccine.external iconJ Infect Dis. 2011 Feb;203(3):316-23.Ray P, Black S, Shinefield H, et al. Risk of rheumatoid arthritis following vaccination with tetanus, influenza and hepatitis B vaccines among persons 15-59 years of ageexternal icon. Vaccine. 2011;29(38):6592-6597.Salmon DA, Akhtar A, Mergler MJ, Vannice KS, Izurieta H, Ball R, et al. Immunization-safety monitoring systems for the 2009 H1N1 monovalent influenza vaccination program.external iconPediatrics. 2011 May;127 Suppl 1:S78-86.Slade B, Gee J, Broder KR, Vellozzi C. Comment on the contribution by Souayah et al., Guillain-Barré syndrome after Gardasil vaccination: Data from Vaccine Adverse Event Reporting System 2006-2009external icon. Vaccine. 2011 Jan;29(5):865-66.Tseng HF, Liu A, Sy L, Marcy SM, Fireman B, Weintraub E, et al. Safety of zoster vaccine in adults from a large managed care cohort: a Vaccine Safety Datalink studyexternal icon. J Intern Med. 2011;271(5):510-520.Williams SE, Pahud BA, Vellozzi C, Donofrio PD, Dekker CL, et al. Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccinationexternal icon.Vaccine. 2011 Oct 26;29(46):8302-8.Williams SE, Klein NP, Halsey N, Dekker CL, Baxter RP, et al. Overview of the clinical consult case review of adverse events following immunization: Clinical Immunization Safety Assessment (CISA) Network 2004-2009external icon. Vaccine. 2011 Sep 16;29(40):6920.Woo EJ, Wise RP, Menschik D, Shadomy SV, Iskander J, Beeler J, et al. Thrombocytopenia after vaccination: Case reports to the US Vaccine Adverse Event Reporting Systemexternal icon, 1990-2008. Vaccine. 2011 Feb;29(6):1319-23.Xu S, Zhang L, Nelson JC, Zeng C, Mullooly J, McClure D, et al. Identifying optimal risk windows for self-controlled case series studies of vaccine safety.external iconStat Med. 2011 Mar;30(7):742-52.Yen C, Jakob K, Esona MD, Peckham X, Rausch J, Hull JJ, et al. Detection of fecal shedding of rotavirus vaccine in infants following their first dose of pentavalent rotavirus vaccine.external iconVaccine. 2011 May;29(24):4151-55.Yih WK, Kulldorff M, Fireman BH, Shui IM, Lewis EM, Klein NP, et al. Active surveillance for adverse events: The experience of the Vaccine Safety Datalink project.external iconPediatrics. 2011 May;127 Suppl 1: S54-S64.Older Vaccine Safety Publications2010Bakare N, Menschik D, Tiernan R, Hua W, Martin D. Severe combined immunodeficiency (SCID) and rotavirus vaccination: Reports to the Vaccine Adverse Events Reporting System (VAERS).external iconVaccine. 2010 Sep;28(40):6609-12.Belongia EA, Irving SA, Shui IM, Kulldorf M, Lewis E, Yin R, et al; Vaccine Safety Datalink Real-time surveillance to assess risk of intussusception and other adverse events after pentavalent, bovine-derived rotavirus vaccineexternal icon. Pedatr Infect Dis J. 2010 Jan;29(1):1-5.Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, et al. Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR. 2010 Aug;59(RR-8):1-62.Goodman MJ, Nordin JD, Belongia EA, Mullooly JP, Baggs J. Henoch-Schonlein purpura and polysaccharide meningococcal vaccine.external iconPediatrics. 2010 Aug;126(2):e325-29.Greene SK, Kulldorff M, Lewis EM, Li R, Yin R, Weintraub ES, et al. Near real-time surveillance for influenza vaccine safety: Proof of concept in the Vaccine Safety Datalink Projectexternal icon. Am J Epidemiol. 2010 Jan;171(2):177-88. 2009 Dec.Huang WT, Chang S, Miller ER, Woo EJ, Hoffmaster AR, Gee JE, et al. Safety assessment of recalled Haemophilus influenzae type b (Hib) conjugate vaccines–United States, 2007-2008external icon. Pharmacoepidemiol Drug Saf. 2010 Mar;19(3):306-310.Huang WT, Gargiullo PM, Broder KR, Weintraub ES, Iskander JK, Klein NP, et al; Vaccine Safety Datalink. Lack of association between acellular pertussis vaccine and seizures in early childhood.external iconPediatrics. 2010 Aug;126(2):263-9.Klein NP, Fireman B, Yih WK, Lewis E, Kulldorff M, Ray P, et al; Vaccine Safety Datalink. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures.external iconPediatrics. 2010;126(1):e1-e8.Klein NP, Gans HA, Sung P, Yasukawa LL, Johnson J, Sarafanov A, et al. Preterm infants’ T cell responses to inactivated poliovirus vaccine.external iconJ Infect Dis. 2010 Jan;201(2):214-22.Li L, Kulldorff M. A conditional maximized sequential probability ratio test for pharmacovigilanceexternal icon. Stat Med. 2010 Jan;29: 284-95, 2010.Lin ND, Kleinman K, Chan KA, Soumerai S, Mehta J, Mullooly JP, et al; Vaccine Safety Datalink. Multiple vaccinations and the risk of medically attended feverexternal icon. Vaccine. 2010 Jun;28(25): 4169-74.Lindsey NP, Staples JE, Jones JF, Sejvar JJ, Griggs A, Iskander J, et al. Adverse event reports following Japanese encephalitis vaccination in the United States, 1999-2009.external iconVaccine. 2010 Dec;29(1):58-64.Marin M, Broder KR, Temte JL, Snider DE, Seward JF; Centers for Disease Control and Prevention (CDC). Use of combination measles, mumps, rubella, and varicella vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2010 May;59(RR-3):1-12.McNeil MM, Broder KR, Vellozzi C, DeStefano F. Risk of fatal adverse events after H1N1 influenza vaccine: Limitations of passive surveillance data.external iconClin Infect Dis. 2010;51(7):871–72; author reply 872-3.Muhammad RD, Haber P, Broder KR, Leroy Z, Ball R, Braun MM, et al. Adverse events following trivalent inactivated influenza vaccination in children: Analysis of the Vaccine Adverse Event Reporting System.external iconPediatr Infect Dis J. 2010 Jan;30(1):e1-e8.Navar-Boggan AM, Halsey NA, Golden WC, Escobar GJ, Massolo M, Klein NP. Risk of fever and sepsis evaluations following routine immunizations in the neonatal intensive care unit.external iconJ Perinatol. 2010 Sep;30(9):604-9.Price CS, Thompson WW, Goodson B, Weintraub ES, Croen LA, Hinrichsen VL, et al. Prenatal and infant exposure to thimerosal from vaccines and immunoglobulins and risk of autismexternal icon. Pediatrics. 2010 Oct;126(4):656-64.Schmidt MA, Crane B, Mullooly JP, Naleway AL. Frequency of medically attended events following rapid revaccination with trivalent inactivated influenza vaccineexternal icon. Vaccine. 2010 Nov;28(49):7713-5.Smith MJ, Woods CR. On-time vaccine receipt in the first year does not adversely affect neuropsychological outcomes.external iconPediatrics. 2010 Jun;125(6):1134-41.Sy LS, Liu IL, Solano Z, Cheetham TC, Lugg MM, Greene SK, et al. Accuracy of influenza vaccination status in a computer-based immunization tracking system of a managed care organization.external iconVaccine. 2010 Jul;28(32):5254-59.Talbot EA, Brown KH, Kirkland KB, Baughman AL, Halperin SA, Broder KR. The safety of immunizing with tetanus-diphtheria-acellular pertussis vaccine (Tdap) less than 2 years following previous tetanus vaccination: Experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak.external iconVaccine. 2010 Nov;28(50):8001-7.Vellozzi C, Broder KR, Haber P, Guh A, Nguyen M, Cano M, et al. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010external icon. Vaccine. 2010 Oct; (45):7248-55.Wong C, Krashin J, Rue-Cover A, Saraiya M, Unger E, Calugar A, et al. Invasive and in situ cervical cancer reported to the vaccine adverse event reporting system (VAERS).external iconJ Womens Health (Larchmt). 2010 Mar; 19(3):365-370.Xu S, Gargiullo P, Mullooly J, McClure , Hambidge SJ, Glanz J. Fitting parametric and semi-parametric conditional Poisson regression models with cox’s partial likelihood in self-controlled case series and matched cohort studies. pdf icon[PDF – 12 pages]external iconJ Data Sci. 2010 Apr;8(2):349-60.Zangwill KM, Yeh SH, Wong EJ, Marcy SM, Eriksen E, Huff KR, et al. Paralytic syndromes in children: Epidemiology and relationship to vaccination. external iconPediatr Neurol. 2010 Mar;42(3):206-12.2009Batra J, Eriksen E, Zangwill K, Lee M, Marcy S, Ward J; Vaccine Safety Datalink. Evaluation of vaccine coverage for low birth weight infants during the first year of life in a large managed care population.external iconPediatrics. 2009 Mar;123(3):951-958.Bonhoeffer J, Bentsi-Echnill, Chen R, Fisher M, Gold M, Hartman K, et al; Brighton Collaboration Methods Working Group. Guidelines for collection, analysis, and presentation of vaccine safety data in pre- and post-licensure clinical studiesexternal icon. Vaccine. 2009 Apr;27(16):2282-8CDC. Safety of influenza A (H1N1) 2009 monovalent vaccines—United States, October 1–November 24, 2009. MMWR. 2009 Dec; 58(48):1351-1356.Donahue JG, Kieke BA, Yih WK, Berger NR, McCauley JS, Baggs J, et al; Vaccine Safety Datalink. Varicella vaccination and ischemic stroke in children: Is there an association?external iconPediatrics. 2009 Feb;123(2)e228–34.Durbin AP, Setse R, Omer SB, Palmer JG, Spaeder JA, Baker J, et al. Monitoring adverse events following yellow fever vaccination using an integrated telephone and internet-based systemexternal icon. Vaccine. 2009 Oct; 27(44):6143-47.Fiore AE, Shay DK, Broder K, Iskander J, Uyeki TM, Mootrey G, et al. Prevention and control of seasonal influenza. MMWR. 2009 Jul;58(RR-8):1-52.Greene SK, Shi P, Dutta-Linn MM, Shoup JA, Hinrichsen VL, Ray P, et al. Accuracy of data on influenza vaccination status at four Vaccine Safety Datalink sites.external iconAm J Prev Med. 2009 Dec;37(6):552-5.Haber P, Sejvar J, Mikaeloff Y, DeStefano F. Vaccines and Guillain-Barré syndrome.external iconDrug Saf. 2009;32(4):309-23.Hazlehurst B, Naleway A, Mullooly J. Detecting possible vaccine adverse events in clinical notes of the electronic medical record.external iconVaccine. 2009 Mar;27(14):2077-83.Hua W, Izurieta HS, Slade B, Belay ED, Haber P, Tiernan R, et al. Kawasaki disease after vaccination: reports to the vaccine adverse event reporting system 1990-2007external icon. Pediatr Infect Dis J. 2009;28(11):943-7.Jackson LA, Yu Onchee, Nelson J, Belongia EA, Hambidge SJ, Baxter R, et al. Risk of medically-attended local reactions following diphtheria toxoid containing vaccines in adolescents and young adults: A Vaccine Safety Datalink Study.external iconVaccine. 2009 Aug;27(36):4912-6.Jackson LA, Onchee Y, Belongia EA, Hambidge SJ, Nelson J, Baxter R, et al. Frequency of medically attended adverse events following tetanus and diphtheria toxoid vaccine in adolescents and young adults: A Vaccine Safety Datalink study.external iconBMC Infect Dis. 2009 Oct;9:165.Jackson LA, Baxter R, Naleway AL, Belongia EA, Baggs J. Patterns of pneumococcal vaccination and revaccination in elderly and non-elderly adults: A Vaccine Safety Datalink study.external iconBMC Infect Dis. 2009 Mar;9:37.Klein NP, Edwards KM, Sparks R, Dekker CL; Clinical Immunization Safety Assessment (CISA) Network. Recurrent sterile abscesses following immunization: A possible association with aluminum adjuvant.external iconBMJ Case Rep. 2009;2009.Klein NP, Kissner J, Aguirre A, Sparks R, Campbell S, Edwards KM, et al. Differential maternal responses to a newly developed vaccine information pamphlet.external iconVaccine 2009; 28:323–8.Naleway AL, Belongia EA, Donahue JG, Kieke BA, Glanz J; Vaccine Safety Datalink. Risk of immune hemolytic anemia in children following immunization.external iconVaccine. 2009 Dec;27(52):7394-7.Nelson JC, Bittner RCL, Bounds L, Zhao S, Baggs J, Donahue JG, et al. Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a Vaccine Safety Datalink Study.external iconAm J Public Health. 2009 Oct;99 Suppl 2:S389-97.Niu MT, Ball R, Woo EJ, Burwen DR, Knippen M, Braun MM; et al. Adverse events after anthrax vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 1990-2007external icon. Vaccine. 2009;27(2):290-7.Patel MM, Haber P, Baggs J, Zuber P, Bines JE, Parashar UD. Intussusception and rotavirus vaccination: a review of the available evidenceexternal icon. Expert Rev Vaccines. 2009;8(11):1555-64.Rosenberg M, Sparks R, McMahon A, Iskander J, Campbell JD, Edwards KM. Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6–23 months of age.external iconVaccine. 2009 Jul;27(32):4278-83.Rue-Cover A, Iskander J, Lyn S, Burwen DR, Gargiullo P, Shadomy S, et al. Death and serious illness following influenza vaccination: A multidisciplinary investigation.external iconPharmacoepidemiol Drug Saf. 2009 Jun;18(6):504-11.Shui IM, Shi P, Dutta-Linn MM, Weintraub ES, Hambidge SJ, Nordin JD, et al; Vaccine Safety Datalink. Predictive value of seizure ICD-9 codes for vaccine safety research.external iconVaccine. 2009 Aug;27(39):5307-12.Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine.external iconJAMA. 2009 Aug;302(7):750-7.Tate J, Curns A, Cortese M, Weintraub E, Hambidge S, Zangwill K, et al. Burden of acute gastroenteritis hospitalizations and emergency department visits in U.S. children that is totally preventable by rotavirus vaccination: a probe study using the now-withdrawn RotaShield vaccine.external iconPediatrics. 2009 Mar;123(3):744-9.Tozzi AE, Bisiacchi P, Tarantino V, De Mei B, D’Elia L, Chariotti F, Salmaso S. Neuropsychological performance 10 years after immunization in infancy with thimerosal-containing vaccines.external iconPediatrics. 2009 Feb;123(2):475-82.Vellozzi C, Burwen DR, Dobardzic A, Ball R, Walton K, Haber P. Safety of trivalent inactivated influenza vaccines in adults: Background for pandemic influenza vaccine safety monitoring.external iconVaccine. 2009 Mar;27(15):2114-20.Wei F, Mullooly JP, Goodman M, McCarty MC, Hanson AM, Crane B, et al. Identification and characteristics of vaccine refusers.external iconBMC Pediatr. 2009 Mar;9:18.Yih WK, Nordin JD, Kulldorff M, Lewis E, Lieu TA, Shi P, et al. An assessment of the safety of adolescent and adult tetanus–diphtheria–acellular pertussis (Tdap) vaccine, using active surveillance for adverse events in the Vaccine Safety Datalink.external iconVaccine. 2009 Jul;27(32):4257-62.2008Asatryan A, Pool V, Chen RT, Kohl KS, Davis RL, Iskander JK; VAERS team. Live attenuated measles and mumps viral strain-containing vaccines and hearing loss: Vaccine Adverse Event Reporting System (VAERS), United States, 1990–2003.external iconVaccine. 2008 Feb 26;26(9):1166-72.Benson PJ, Jackson LA, Rees TG, Dunn JB. Changes in DT vaccine frequency and indications for use following introduction of DTaP vaccine.external iconHum Vaccin. 2008 May-Jun;4(3):234-7.Broder KR, Cohn AC, Schwartz B, Klein JD, Fisher MM, Fishbein DB, et al; Working Group on Adolescent Prevention Priorities. Adolescent immunizations and other clinical preventive services: A needle and a hook?external iconPediatrics. 2008 Jan;121 Suppl 1:S25-34.Chapman LE, Iskander JK, Chen RT, Neff J, Birkhead GS, Poland G, et al. A process for sentinel case review to assess causal relationships between smallpox vaccination and adverse outcomes, 2003–2004.external iconClin Infect Dis. 2008 Mar;46 Suppl 3:S271-93.Chaves SS, Haber P, Walton K, Wise RP, Izurieta HS, Schmid DS, et al. Safety of varicella vaccine after licensure in the United States: experience from reports to the Vaccine Adverse Event Reporting System, 1995–2005.external iconJ Infect Dis. 2008 Mar 1;197 Suppl 2:S170-7.Clayton HA, Cortese MM, Payne DC, Bartlett DL, Zimmerman LA, Williams WG, Wang M, Stockman LJ, Parashar U, Baggs J. Rotavirus vaccination coverage and adherence to the Advisory Committee on Immunization Practices (ACIP)-recommended vaccination schedule—United States, February 2006–May 2007. MMWR. 2008 Apr;57(15):398-401.Fishbein DB, Broder KR, Markowitz L, Messonnier N. New, and some not-so-new, vaccines for adolescents and diseases they prevent.external iconPediatrics. 2008 Jan;121 Suppl 1:S5-14.France EK, Glanz JM, Xu S, Hambidge S, Yamasaki K, Black SB, et al; Vaccine Safety Datalink. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children.external iconPediatrics. 2008 Mar;121(3):e687-92.Gidudu J, Kohl KS, Halperin S, Hammer SJ, Heath PT, Hennig R, et al; The Brighton Collaboration Local Reactions Working Group for A Local Reaction at or near Injection Site. A local reaction at or near injection site: Case definition and guidelines for collection, analysis, and presentation of immunization safety data.external iconVaccine. 2008 Dec;26(52):6800-13.Glanz JM, France EK, Xu S, Hayes T, Hambidge S. A population-based, multisite cohort study of the predictors of chronic idiopathic thrombocytopenic purpura in children.external iconPediatrics. 2008 Mar;121(3):e506-12.Haber P, Patel M, Izurieta HS, Baggs J, Gargiullo P, Weintraub E, et al. Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007.external iconPediatrics. 2008 Jun;121(6):1206-12.Halsey NA. The Human Papillomavirus Vaccine and Risk of Anaphylaxisexternal icon. [Commentary]. CMAJ. 2008 Sep 9;179(6):509-10. Erratum in: CMAJ. 2008 Sep 23; 179(7):678.Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: Recommendations of the Advisory Committee on Immunization Practices (ACIP).external iconMMWR. 2008 Jun;57(RR-5):1-30; quiz CE2-4.Iskander J, Broder K. Monitoring the safety of annual and pandemic influenza vaccines: lessons from the US experience.external iconExpert Rev Vaccines. 2008 Feb;7(1):75-82.Iskander J, Gidudu J, Arboleda N, Huang WT. Selected major issues in vaccine safetyexternal icon. Ann Nestlé. 2008;66:93-102.Klein NP, Massolo ML, Greene J, Dekker CL, Black S, Escobar GJ; Vaccine Safety Datalink. Risk factors for developing apnea after immunization in the neonatal intensive care unit.external iconPediatrics. 2008 Mar;121(3):463-9.Kohl K, Magnus M, Ball R, Halsey N, Shadomy S, et al. Applicability, Reliability, Sensitivity, and Specificity of Six Brighton Collaboration Standardized Case Definitions for Adverse Events Following Immunizationexternal icon. Vaccine. 2008 Nov 25; 26(50):6349–60.Leung J, Rue A, Lopez A, Ortega-Sanchez IR, Harpaz R, Guris D, et al. Varicella outbreak reporting, response, management, and national surveillance.external iconJ Infect Dis. 2008 Mar 1;197 Suppl 2:S108-13.Lindsey NP, Schroeder BA, Miller ER, Braun MM, Hinckley AF, Marano N, et al. Adverse event reports following yellow fever vaccinationexternal icon. Vaccine. 2008;26(48):6077-82.McClure DL, Glanz JM, Xu S, Hambidge SJ, Mullooly JP, Baggs J. Comparison of epidemiologic methods for active surveillance of vaccine safety.external iconVaccine. 2008 Jun;26(26):3341-5.McMahon AW, Iskander JK, Haber P, Braun MM, Ball R. Inactivated influenza vaccine (IIV) in children < 2 years of age: Examination of selected adverse events reported to the Vaccine Adverse Event Reporting System (VAERS) after thimerosal-free or thimerosal-containing vaccine.external iconVaccine. 2008 Jan;26(3):427-9.Morgan J, Roper MH, Sperling L, Schieber RA, Heffelfinger JD, Casey CG, et al. Myocarditis, pericarditis, and dilated cardiomyopathy after smallpox vaccination among civilians in the United States, January–October 2003.external iconClin Infect Dis. 2008 Mar 15;46 Suppl 3:S242-50.Nachamkin I, Shadomy SV, Moran AP, Cox N, Fitzgerald C, Ung H, et al. Anti-ganglioside antibody induction by swine (A/NJ/1976/H1N1) and other influenza vaccines: Insights into vaccine-associated Guillain-Barre syndrome.external iconJ Infect Dis. 2008 Jul 15;198(2):226-33.Rennels M, Black S, Woo E, Campbell S, Edwards KM. Safety of a fifth dose of diphtheria and tetanus toxoid and acellular pertussis vaccine in children experiencing extensive, local reactions to the fourth doseexternal icon. Pediatr Infect Dis J. 2008 May;27(5):464-5.Sutherland A, Izurieta H, Ball R, Braun MM, Miller ER, Broder KR, et al; Centers for Disease Control and Prevention. Syncope after vaccination—United States, January 2005–July 2007. MMWR. 2008 May;57(17):457-60.Swerdlow DL, Roper MH, Morgan J, Schieber RA, Sperling LS, Sniadack MM, et al; Smallpox Vaccine Cardiac Adverse Events Working Group. Ischemic cardiac events during the Department of Health and Human Services Smallpox Vaccination Program, 2003.external iconClin Infect Dis. 2008 Mar 15;46 Suppl 3:S234-41.Tatti KM, Slade BA, Patel M, Messonier NR, Jackson T, Kirkland K, et al. Real-time polymerase chain reaction detection of Bordetella pertussis DNA in acellular pertussis vaccines.external iconPediatr Infect Dis J. 2008 Jan;27(1):73-4.Thomas TN, Reef S, Neff L, Sniadack MM, Mootrey GT. A review of the smallpox vaccine adverse events active surveillance system.external iconClin Infect Dis. 2008 Mar 15;46 Suppl 3:S212-20.Wood RA, Berger M, Dreskin SC, Setse R, Engler RJM, Dekker CL, et al; Hypersensitivity Working Group of the Clinical Immunization Safety Assessment (CISA) Network. An algorithm for treatment of patients with hypersensitivity reactions after vaccines.external iconPediatrics. 2008 Sep;122(3):e771-7.2007Beigel J, Kohl KS, Brinley F, Graham PL, Khuri-Bulos N, LaRussa PS, et al. Generalized vaccinia as an adverse event following exposure to vaccinia virus: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data.external iconVaccine. 2007;25(31):5745–5753.Beigel J, Kohl KS, Khuri-Bulos N, Bravo L, Nell P, Marcy SM, et al. Rash including mucosal involvement: Case definition and guidelines for collection, analysis, and presentation of immunization safety data.external iconVaccine. 2007;25(31):5697–5706.Belongia E, Izurieta H, Braun MM, Ball R, Haber P, Baggs J, et al. Postmarketing monitoring of intussusception after RotaTeq vaccination – United States, February 1, 2006-February 15, 2007external icon. MMWR. 2007 Mar 16;56(10):218-22.Buettcher M, Baer G, Bonhoeffer J, Schaad UB, Heininger U. Three-year surveillance of intussusception in children in Switzerland.external iconPediatrics. 2007;120(3):473–480.Buettcher M, Heininger U, Braun M, Bonhoeffer J, Halperin S, Heijbel H, et al. Hypotonic-hyporesponsive episode (HHE) as an adverse event following immunization in early childhood: Case definition and guidelines for data collection, analysis, and presentation.external iconVaccine. 2007;25(31):5875–5881.DeStefano F, Weintraub ES, Chen RT. Hepatitis B vaccine and risk of multiple sclerosisexternal icon[letter]. Pharmacoepidemiol Drug Saf. 2007 Jun;16(6):705-7, author reply 707-8.Fiore AE, Shay DK, Haber P, Iskander JK, Uyeki TM, Mootrey G, et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007external icon. MMWR Recomm Rep. 2007 Jul 13; 56(RR-6):1-54.Graham PL, LaRussa PS, Kohl KS; Brighton Collaboration Vaccinia Virus Adverse Event Working Group for Robust Take. Robust take following exposure to vaccinia virus: Case definition and guidelines of data collection, analysis, and presentation of immunization safety data.external iconVaccine. 2007 Aug 1;25(31):5763-70.Haber MJ, Shay DK, Davis XM, Patel R, Jin X, Weintraub E, et al. Effectiveness of interventions to reduce contact rates during a simulated influenza pandemic.external iconEmerg Infect Dis. 2007 Apr;13(4):581-9.Haber P, Slade B, Iskander J. Guillain-Barré Syndrome (GBS) after vaccination reported to the United States Vaccine Adverse Event Reporting System (VAERS) in 2004 [Letter]external icon. Vaccine. 2007;25(48):8101.Halperin S, Kohl KS, Gidudu J, Ball L, Hammer SJ, Heath P, et al. Cellulitis at injection site: Case definition and guidelines for collection, analysis, and presentation of immunization safety data.external iconVaccine. 2007;25(31):5803–5820.Hirichsen V, Kruskal B, O’Brien MA, Lieu TA, Platt R; Vaccine Safety Datalink Team. Using electronic medical records to enhance detection and reporting of vaccine adverse events.external iconJ Am Med Inform Assoc. 2007 Nov-Dec;14(6):731-5.Jackson LA, Neuzil KM, Nahm MH, Whitney CG, Yu O, Nelson JC, et al. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.external iconVaccine. 2007;25(20):4029–4037.Jackson ML, Nelson JC, Chen RT, Davis RL, Jackson LA; Vaccine Safety Datalink team. Vaccines and changes in coagulation parameters in adults on chronic warfarin therapy: a cohort study.external iconPharmacoepidemiol Drug Saf. 2007 Jul;16(7):790-6.Jones JF, Kohl KS, Ahmadipour N, Bleijenberg G, Buchwald D, Evengard B, et al. Fatigue: Case definition and guidelines for collection, analysis, and presentation of immunization safety data.external iconVaccine. 2007;25(31):5685–5696.Jorch G, Tapiainen T, Bonhoeffer J, Fischer TK, Heininger U, Hoet B, et al. Unexplained sudden death, including sudden infant death syndrome (SIDS), in the first and second years of life: Case definition and guidelines for collection, analysis, and presentation of immunization safety data.external iconVaccine. 2007;25(31):5707–5716.Klein NP, Fireman B, Enright A, Ray P, Black S, Dekker CL; Clinical Immunization Safety Assessment Network. A role for genetics in the immune response to the varicella vaccine.external iconPediatr Infect Dis J. 2007 Apr;26(4):300-5.Kohl KS, Ball L, Gidudu J, Hammer SJ, Halperin S, Heath P, et al. Abscess at injection site: Case definition and guidelines for collection, analysis, and presentation of immunization safety data.external iconVaccine. 2007;25(31):5821–5838.Kohl KS, Gidudu J, Bonhoeffer J, Braun MM, Buettcher M, Chen RT, et al. The development of standardized case definitions and guidelines for adverse events following immunization.external iconVaccine. 2007;25(31):5671–5674.Kohl KS, Walop W, Gidudu J, Ball L, Halperin S, Hammer SJ, et al. Induration at or near injection site: Case definition and guidelines for collection, analysis, and presentation of immunization safety data.external iconVaccine. 2007;25(31):5839–5857.Kohl KS, Walop W, Gidudu J, Ball L, Halperin S, Hammer SJ, et al. Swelling at or near injection site: Case definition and guidelines for collection, analysis and presentation of immunization safety data.external iconVaccine. 2007;25(31):5858–5874.Lieu TA, Kulldorff M, Davis RL, Lewis EM, Weintraub E, Yih K, et al. Real-time vaccine safety surveillance for the early detection of adverse events.external iconMed Care. 2007 Oct;45(10 Supl 2):S89-95.McNeil MM, Ma GW, Aranas A, Payne DC, Rose CE Jr. A comparative assessment of immunization records in the Defense Medical Surveillance System and the Vaccine Adverse Event Reporting Systemexternal icon. Vaccine. 2007 Apr 30;25(17):3428-36.Miller ER, Iskander J, Pickering S, Varricchio F. How can you promote vaccine safety?external iconNursing. 2007;37(4):58–63.Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs.external iconVaccine. 2007 Jun 28;25(27):5086-96.Mullooly JP, Bridges CB, Thompson WW, Chen J, Weintraub E, Jackson LA, et al. Influenza- and RSV-associated hospitalizations among adults.external iconVaccine. 2007 Jan 15;25(5):846-55.Mullooly JP, Schuler R, Barrett M, Maher JE. Vaccines, antibiotics, and atopy.external iconPharmacoepidemiol Drug Saf. 2007 Mar;16(3):275-88.Nell P, Kohl KS, Graham PL, LaRussa PS, Marcy SM, Fulginiti VA, et al. Progressive vaccinia as an adverse event following exposure to vaccinia virus: Case definition and guidelines of data collection, analysis, and presentation of immunization safety data.external iconVaccine. 2007;25(31):5735–5744.Nell P, Kohl KS, Graham PL, LaRussa PS, Marcy SM, Fulginiti VA, et al. Eczema vaccinatum as an adverse event following exposure to vaccinia virus: case definition & guidelines of data collection, analysis, and presentation of immunization safety data.external iconVaccine. 2007;25(31):5725–5734.Payne DC, Aranas A, McNeil MM, Duderstadt S, and Rose Jr. CE. Concurrent vaccinations and U.S. military hospitalizationsexternal icon. Ann. Epidemiol. 2007 Sep;17(9):697-703.Payne DC, Franzke LH, Stehr-Green PA, Schwartz B, and McNeil MM. Development of the Vaccine Analytic Unit’s research agenda for investigating potential adverse events associated with anthrax vaccine adsorbedexternal icon. Pharmacoepidemiol Drug Saf. 2007 Jan;16(1):46-54.Payne DC, Rose Jr. CE, Aranas A, Zhang Y, Tolentino H, Weston E, et al. Assessment of anthrax vaccination data in the Defense Medical Surveillance System, 1998-2004external icon. Pharmacoepidemiol Drug Saf. 2007 Jun;16(6):605-11.Rüggeberg JU, Gold MS, Bayas JM, Blum MD, Bonhoeffer J, Friedlander S, et al. Anaphylaxis: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data.external iconVaccine. 2007;25(31):5675–5684.Sejvar JJ, Kohl KS, Bilynsky R, Blumberg D, Cvetkovich T, Galama J, et al. Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): Case definitions and guidelines for collection, analysis, and presentation of immunization safety data.external iconVaccine. 2007 Aug 1;25(31):5771-92Tapiainen T, Prevots R, Izurieta HS, Abramson J, Bilynsky R, Bonhoeffer J, et al. Aseptic meningitis: Case definition and guidelines for collection, analysis and presentation of immunization safety data.external iconVaccine. 2007 Aug 1;25(31):5793-802.Thompson WW, Price C, Goodson B, Shay DK, Benson P, Hinrichsen VL, et al. Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years.external iconN Engl J Med. 2007 Sep 27;357(13):1281-92.Tolentino HD, Matters MD, Walop W, Law B, Tong W, Liu F, Fontelo P, Kohl K, and Payne DC. A UMLS-based spell checker for natural language processing in vaccine safety 2007; 7: 3. external iconWenger P, Oleske JM, Kohl KS, Fisher MC, Brien JH, Graham PL, et al. Inadvertent inoculation as an adverse event following exposure to vaccinia virus: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data.external iconVaccine.2007;25(31):5754–5762.Wise RP, Bonhoeffer J, Beeler J, Donato H, Downie P, Matthews D, et al. Thrombocytopenia: Case definition and guidelines for collection, analysis, and presentation of immunization safety data.external iconVaccine. 2007 Aug 1;25(31):5717-24.Woo EJ, Ball R, Landa R, Zimmerman AW, Braun MM; VAERS Working Group. Developmental regression and autism reported to the Vaccine Adverse Event Reporting Systemexternal icon. Autism. 2007; 11(4):301-10.Wood R, Setse R, Halsey NA; Clinical Immunization Safety Assessment Network Hypersensitivity Working Group. Irritant skin test reactions to common vaccines.external iconJ Allergy Clin Immunol. 2007 Aug;120(2):478-81.Yu O, Bohlke K, Hanson CA, Delaney K, Rees TG, Zavitkovsky A, et al. Hepatitis B vaccine and risk of autoimmune thyroid disease: A Vaccine Safety Datalink studyexternal icon. Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):736-45.2006Bines JE, Liem NT, Justice F, Son TN, Carlin JB, de Campo M, et al. Validation of a clinical case definition for acute intussusception in infants in Vietnam and Australia.external iconBull World Health Organ. 2006 Jul;84(7):569-75.Broder KR, Cortese MM, Iskander JK, Kretsinger K, Slade BA, Brown KH, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: Use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP)external icon. MMWR Recomm Rep. 2006 Mar 24; 55(RR-3):1-34.CDC. Update: Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine—United States, October 2005–February 2006. MMWR. 2006;55(13):364–366.DiMiceli L, Pool V, Kelso JM, Shadomy SV, Iskander J; VAERS Team. Vaccination of yeast sensitive individuals: Review of safety data in the US vaccine adverse event reporting system (VAERS).external iconVaccine. 2006;24(6):703–707.Fowler GL, Baggs JM, Weintraub ES, Martin SW, McNeil MM, Gust DA. Factors influencing laboratory workers’ decisions to accept or decline anthrax vaccine adsorbed (AVA): Results of a Ddcision-making study in CDC’s anthrax vaccination programexternal icon. Pharmacoepidemiol Drug Saf.2006 Dec;15(12):880-8.France EK, Smith-Ray R, McClure D, Hambidge S, Xu S, Yamasaki K, et al. Impact of maternal influenza vaccination during pregnancy on the incidence of acute respiratory illness visits among infants.external iconArch Pediatr Adolesc Med. 2006 Dec;160(12):1277-83.Glanz JM, McClure DL, Xu S, Hambidge SJ, Lee M, Kolczak MS, et al. Four different study designs to evaluate vaccine safety were equally validated with contrasting limitations.external iconJ Clin Epidemiol. 2006 Aug;59(8):808-18.Hambidge SJ, Glanz JM, France EK, McClure D, Xu S, Yamasaki K, et al. Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old.external iconJAMA. 2006 Oct 25;296(16):1990-7.Iskander J, Pool V, Zhou W, English-Bullard R; VAERS Team. Data mining in the US using the Vaccine Adverse Event Reporting System.external iconDrug Saf. 2006;29(5):375-84.Jackson LA, Nelson JC, Whitney CG, Neuzil KM, Benson P, Malais D, et al. Assessment of the safety of a third dose of pneumococcal polysaccharide vaccine in the Vaccine Safety Datalink population.external iconVaccine. 2006;24(2):151–156.Jackson LA, Neuzil KM, Baggs J, Davis RL, Black S, Yamasaki KM, et al. Compliance with the recommendations for 2 doses of trivalent inactivated influenza vaccine in children less than 9 years of age receiving influenza vaccine for the first time: A Vaccine Safety Datalink study.external iconPediatrics. 2006;118(5):2032–2037.Lin ND, Kleinman K, Chan KA, Yu XJ, France EK, Wei F, et al. Variation in hepatitis B immunization coverage rates associated with provider practices after the temporary suspension of the birth dose.external iconBMC Pediatr. 2006 Nov 13;6:31.Miller ER, Woo EJ. Time to prevent injuries from postimmunization syncopeexternal icon. Nursing. 2006; 36(12 Pt.1):20.Muralles AA, Ray P, Black S, Shinefield H, Casey CG, Campbell S, et al. Active telephone surveillance to evaluate adverse events among civilian smallpox vaccine recipients.external iconVaccine. 2006;24(4):476–484.Payne DC, Rose CE Jr, Kerrison J, Aranas A, Duderstadt S, McNeil MM. Anthrax vaccination and risk of optic neuritis in the United States military, 1998-2003external icon. Arch. Neurology 2006;63:871-875.Prosser LA, Bridges CB, Uyeki TM, Hinrichsen VL, Meltzer MI, Noelle-Angelique MM, et al. Health benefits, risks, and cost-effectiveness of influenza vaccination of children.external iconEmerg Infect Dis. 2006 Oct;12(10):1548-58.Ray P, Hayward J, Michelson D, Lewis E, Schwalbe J, Black S, et al. Encephalopathy after whole-cell pertussis or measles vaccination: Lack of evidence for a causal association in a retrospective case-control study.external iconPediatr Infect Dis J. 2006 Sep;25(9):768-73.Sekaran N, Edwards, K. Extensive swelling reaction associated with diphtheria and tetanus toxoids and acellular pertussis vaccineexternal icon. Pediatr Infect Dis J. 2006 Apr; 25(4):374-5.Tapiainen T, Bär G, Bonhoeffer J, Heininger U. Evaluation of The Brighton Collaboration case definition of acute intussusception during active surveillance.external iconVaccine. 2006 Feb 27;24(9):1483-7.Varricchio F, Reed J; VAERS Working Group. Follow-up study of medication errors reported to the Vaccine Adverse Event Reporting System (VAERS).external iconSouth Med J. 2006 May;99(5):486-9.Vellozzi C, Mitchell T, Miller E, Casey CG, Eidex RB, Hayes EB. Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) and corticosteroid therapy: Eleven United States cases, 1996-2004external icon. Am J Trop Med Hyg. 2006 Aug;75(2):333-6.Vermeer-de Bondt PE, Dzaferagić A, David S, van der Maas NA. Performance of The Brighton Collaboration case definition for hypotonic–hyporesponsive episode (HHE) on reported collapse reactions following infant vaccinations in the Netherlands.external iconVaccine. 2006 Nov 30;24(49-50):7066-70.Woo EJ, Ball R, Braun M, Clark T, Rosenstein Messonnier N, Wharton M, et al. Update: Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine—United States, June 2005–September 2006. MMWR. 2006 Oct 20;55(41):1120-4.Woo EJ, Ball R, Landa R, Zimmerman AW, Braun MM; VAERS Working Group. Developmental regression and autism reported to the Vaccine Adverse Event Reporting System.external iconAutism. 2007 Jul;11(4):301-10.Woo EJ, Miller NB, Ball R; VAERS Working Group. Adverse events after hepatitis A B combination vaccine.external iconVaccine. 2006;24(14):2685–2691.2005Baggs J, Chen R, Damon I, Rotz L, Allen C, Fullerton K, et al. Safety profile of smallpox vaccine: Insights from the pre-event smallpox vaccination programexternal icon. Clin Infect Dis. 2005;40(8):1133-40.Belongia EA, Naleway A, Kieke B, Qutaishat S, Casey C, Shay DK, et al. Validation of a screening instrument to identify persons for exclusion from smallpox vaccinationexternal icon. Clin Infect Dis. 2005 Feb 15;40(4):620-3.Bloom S, Rguig A, Berraho A, Zniber L, Bouazzaoui N, Zaghloul Z, et al. Congenital rubella syndrome burden in Morocco: a rapid retrospective assessmentexternal icon. Lancet. 2005 Jan 8;365(9454):135-41.Casey CG, Iskander JK, Roper MH, Mast EE, Wen XJ, Tӧrӧk TJ, et al. Adverse events associated with smallpox vaccination in the United States, January-October 2003external icon. JAMA. 2005 Dec 7;294(21):2734-43.CDC. Guillain-Barré syndrome among recipients of Menactra® meningococcal conjugate vaccine—United States, June–July 2005. MMWR Dispatch. 2005;54:1-3.Davis RL, Kolczak M, Lewis E, Nordin J, Goodman M, Shay DK, et al. Active surveillance of vaccine safety: a system to detect early signs of adverse eventsexternal icon. Epidemiology. 2005 May;16(3):336-41.DeStefano F, Weintraub ES, Chen RT. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study [letter]external icon. Neurology. 2005 Apr 12;64(7):1317; author reply 1318.Gust D, Brown C, Sheedy K, Hibbs B, Weaver D, Nowak G. Immunization attitudes and beliefs among parents: Beyond a dichotomous perspectiveexternal icon. Am J Health Behav. 2005 Jan-Feb;29(1):81-92.Gust DA, Kennedy A, Shui I, Smith PJ, Nowak G, Pickering LK. Parent Attitudes Toward Immunizations and Healthcare Providers: The Role of Informationexternal icon. Am J Preventive Health. 2005 Aug;29(2):105-12.Iskander J, Haber P, Herrera G. Monitoring vaccine safety during an influenza pandemicexternal icon. Yale J Biol Med. 2005; 78(5):265-75.Izurieta HS, Haber P, Wise RP, Iskander J, Pratt D, Mink C, et al. Adverse events reported following live, cold-adapted, intranasal influenza vaccineexternal icon. JAMA. 2005 Dec 7;294(21):2720-5.Jackson LA, Neuzil KM, Whitney CG, Starkovich P, Dunstan M, Yu O, et al. Safety of varying dosages of 7-valent pneumococcal protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccineexternal icon. Vaccine. 2005;23(28):3697-703.Kennedy A, Brown C, Gust D. Vaccine beliefs of parents who oppose compulsory vaccinationexternal icon. Public Health Rep. 2005 May-Jun; 120(3): 252–258.Kennedy A, Gust D. Parental vaccine beliefs and child’s school typeexternal icon. J Sch Health. 2005 Sep;75(7):276-80.Khromava AY, Eidex RB, Weld LH, Kohl KS, Bradshaw RD, Chen RT, et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse eventsexternal icon. Vaccine. 2005 May 9;23(25):3256-63.Kohl KS, Bonhoeffer J, Braun MM, Chen RT, Duclos P, Heijbel H, et al. The Brighton Collaboration: Creating a global standard for case definitions (and guidelines) for adverse events following immunizationexternal icon. In Advances in Patient Safety: From Research to Implementation. Henriksen K, Battles JB, Marks ES, et al., eds. Rockville (MD): Agency for Healthcare Research and Quality (US); 2005 Feb.Martin SW, Tierney BC, Aranas A, Rosenstein NE, Franzke LH, Apicella L, et al. An overview of adverse events reported by participants in CDC’s anthrax vaccine and antimicrobial availability program.external icon. Pharmacoepidemiol Drug Saf. 2005 Jun;14(6):393-401.McMahon AW, Iskander J, Haber P, Chang S, Woo EJ, Braun MM, etc. Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003external icon. Pediatrics. 2005;115(2):453-60.Lewis N, Black S, Weintraub E, Baggs J, Thompson W, DeStefano F, et al. Rapid assessment of influenza vaccination coverage among HMO members—Northern California influenza seasons, 2001–02 through 2004–05. MMWR. 2005;54(27):676-678.Mandell DS, Thompson WW, Weintraub ES, DeStefano F, Blank MB. Trends in diagnosis rates for autism and ADHD at hospital discharge in the context of other psychiatric diagnosesexternal icon. Psychiatr Serv. 2005 Jan;56(1):56-62.McMahon AW, Iskander J, Haber P, Chang S, Woo EJ, Braun MM, et al. Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003external icon. Pediatrics. 2005;115(2):453-60.Papania MJ, Strebel PM. Measles surveillance: the importance of finding the tip of the iceberg [commentary]external icon. Lancet. 2005 Jan 8;365(9454):100-1.Rollison D, Helzlsouer K, Halsey N, Shah K, and Viscidi R. Markers of past infection with simian virus 40 (SV40) and risk of incident non-Hodgkin lymphoma in a Maryland cohortexternal icon. Cancer Epidemiol Biomarkers Prev. 2005 June; 14(6) 1448-1452.Sejvar J, Boneva R, Lane JM, Iskander J. Severe headaches following smallpox vaccinationexternal icon. Headache. 2005 Jan;45(1):87-8.Sejvar JJ, Labutta RJ, Chapman LE, Grabenstein JD, Iskander J, Lane JM. Neurologic adverse events associated with smallpox vaccination in the United States, 2002-2004external icon. JAMA. 2005 Dec 7;294(21):2744-50.Shui I, Kennedy A, Wooten K, Schwartz B, Gust D. Factors influencing African American mothers’ concerns about immunization safety: A summary of focus group findings in Atlantaexternal icon. J Natl Med Assoc. 2005 May;97(5):657-66.Vellozzi CJ, Lane MJ, Averhoff F, Mauer T, Norton S, Damon I, Casey C. Generalized vaccinia, progressive vaccinia andeczema vaccinatum are rare following smallpox vaccination: United States Surveillance, 2003external icon. Clin Infect Dis. 2005 Sep 1;41(5):689-97. Epub 2005 Jul 26.Verstraeten T, Davis R, Destefano F. Immunity to tetanus is protective against the development of multiple sclerosisexternal icon. Med Hypotheses. 2005;65(5):966-9.Yeung LF, Lurie P, Dayan G, Eduardo E, Britz PH, Redd SB, et al. A limited measles outbreak in a highly vaccinated US boarding schoolexternal icon. Pediatrics. 2005 Dec;116(6):1287-91.2004Begier EM, Burwen DR, Haber P, Ball R; Vaccine Adverse Event Reporting System Working Group. Postmarketing safety surveillance for typhoid fever vaccines from the Vaccine Adverse Event Reporting System, July 1990 through June 2002external icon. Clin Infect Dis. 2004;38(6):771-9.Begier EM, Langford CA, Sneller MC, Wise RP, Ball R; VAERS Working Group. Polyarteritis nodosa reports to the Vaccine Adverse Event Reporting System (VAERS): Implications for assessment of suspected vaccine-provoked vasculitisexternal icon. J Rheumatol. 2004;31(11):2181-8.Bines JE, Kohl KS, Forster J, Zanardi LR, Davis RL, Hansen J, et al. Acute intussusception in infants and children as an adverse event following immunization: Case definition and guidelines of data collection, analysis, and presentationexternal icon. Vaccine. 2004 Jan 26;22(5-6):569-74.Bonhoeffer J, Kohl KS, Chen RT, Duclos P, Heijbel H, Heininger U, et al. Standardized case definitions of adverse events following immunization (AEFI)external icon. Vaccine. 2004 Jan 26;22(5-6):547-50.Bonhoeffer J, Vermeer P, Halperin S, Kempe A, Music S, Shindman J, et al. Persistent crying in infants and children as an adverse event following immunization: Case definition and guidelines for data collection, analysis, and presentationexternal icon. Vaccine. 2004 Jan 26;22(5-6):586-91.Bonhoeffer J, Gold MS, Heijbel H, Vermeer P, Blumberg D, Braun M, et al. Hypotonic-Hyporesponsive Episode (HHE) as an adverse event following immunization: Case definition and guidelines for data collection, analysis, and presentationexternal icon. Vaccine. 2004 Jan 26;22(5-6):563-8.Bonhoeffer J, Menkes J, Gold MS, de Souza-Brito G, Fisher MC, Halsey N, et al. Generalized convulsive seizure as an adverse event following immunization: Case definition and guidelines for data collection, analysis, and presentationexternal icon. Vaccine. 2004 Jan 26;22(5-6):557-62.Chen R. Evaluation of vaccine safety after the events of 11 September 2001: Role of cohort and case-control studiesexternal icon. Vaccine. 2004 May 7;22(15-16):2047-53.Freed GL, Clark SJ, Hibbs BH, Santoli JM. Parental vaccine safety concerns. The experience of pediatricians and family physiciansexternal icon. Am J Prev Med. 2004 Jan;26(1):11-4.Haber P, Zanardi LR, Chen RT, Mootrey GT, Pless R, English R, et al. An analysis of rotavirus vaccine reports to the Vaccine Adverse Event Reporting System: More than intussusception alone?external iconPediatrics. 2004 Apr;113(4):e353-9.Haber P, DeStefano F, Angulo FJ, Iskander J, Shadomy SV, Weintraub E, et al. Guillain-Barré syndrome following influenza vaccinationexternal icon. JAMA. 2004 Nov 24;292(20):2478-81Iskander JK, Miller ER, Chen RT. The role of the Vaccine Adverse Event Reporting system (VAERS) in monitoring vaccine safetyexternal icon. Pediatr Ann. 2004;33(9):599-606.Kohl KS, Marcy SM, Blum M, Connell Jones M, Dagan R, et al. Fever After Immunization: Current concepts and improved future scientific understandingexternal icon. Clin Infect Dis. 2004 Aug 1;39(3):389-94.Marcy SM, Kohl KS, Dagan R, Nalin D, Blum M, Connell Jones M, et al. Fever as an adverse event following immunization: Case definition and guidelines of data collection, analysis, and presentationexternal icon. Vaccine. 2004 Jan 26;22(5-6):551-6.Muetsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, et al. Inactivated intranasal influenza vaccine and the risk of Bell’s Palsy in Switzerlandexternal icon. N Engl J Med. 2004 Feb 26;350(9):896-903.O’Brien MA, Uyeki TM, Shay DK, Thompson WW, Kleinman K, McAdam A, et al. Incidence of outpatient visits and hospitalizations related to influenza in infants and young childrenexternal icon. Pediatrics. 2004 Mar;113(3 Pt 1):585-93.Rothstein E, Kohl KS, Ball L, Halperin SA, Halsey N, Hammer SJ, et al. Nodule at injection site as an adverse event following immunization: Case definition and guidelines for data collection, analysis, and presentationexternal icon. Vaccine. 2004 Jan 26;22(5-6):575-85.Steinberg EB, Bishop R, Haber P, Dempsey AF, Hoekstra RM, Nelson JM, et al. Typhoid fever in travelers: Who should be targeted for prevention?external iconClin Infect Dis. 2004 Jul 15;39(2):186-91. Epub 2004 Jul 1.Varricchio F, Iskander J, DeStefano F, Ball R, Pless R, Braun MM, et al. Understanding vaccine safety: Information from the Vaccine Adverse Event Reporting Systemexternal icon. Pediatr Infect Dis J. 2004 Apr;23(4):287-94.Wise RP, Iskander J, Pratt RD, Campbell S, Ball R, Pless RP, et al. Postlicensure safety surveillance for 7-valent pneumococcal conjugate vaccineexternal icon. JAMA. 2004;292(14):1702-10.Zhou WG, Pool V, Destefano F, Iskander JK, Haber P, Chen RT, and The VAERS Working Group. A potential signal of Bell’s palsy after parenteral inactivated influenza vaccines: Reports to the Vaccine Adverse Event Reporting System (VAERS) – United States, 1991-2001external icon. Pharmacoepidemiol Drug Saf. 2004 Aug;13(8):505-10.2003Bohlke K, Davis RL, Marcy SM, Braun MM, DeStefano F, et al. The risk of anaphylaxis following vaccination of children and adolescentsexternal icon. Pediatrics. 2003;112:815-20.CDC. Update: Multistate outbreak of monkeypox- Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003. MMWR. 2003;52:642-646.Chen RT, Lane JM. Myocarditis: The unexpected return of smallpox vaccine adverse eventsexternal icon. Lancet. 2003 Oct 25;362(9393):1345-6.Cono J, Casey CG, Bell DM. Smallpox vaccination and adverse reactions: Guidance for clinicians. MMWR. 2003;52(No. RR-4):1-28.DeStefano F, VerstraetenT, Jackson LA, Okoro CA, Benson P, Black SB, et al. Vaccinations and risk of central nervous system demyelinating diseases in adultsexternal icon. Arch Neurol. 2003;60:504-9.DeStefano F, Verstraeten T, Chen RT. Hepatitis B vaccine and risk of multiple sclerosisexternal icon. Expert Rev of Vaccines. 2003;2(1):21-29.Gust DA, Woodruff R, Kennedy A, Brown C, Sheedy K, Hibbs B. Parental perceptions surrounding risks and benefits of immunizationsexternal icon. Semin Pediatr Infect Dis. 2003 Jul;14(3):207-12.Haber P, DeStefano F. Influenza vaccination and Guillain Barré syndromeexternal icon. Clin Immunol. 2003; 109(3):359; author reply 360-1.Hutwagner L, Thompson WW, Seeman GM, Treadwell T. The bioterrorism preparedness and response Early Aberration Reporting System (EARS)external icon. J Urban Health. 2003 Jun;80(2 Suppl 1):i89-96.Jackson LA, Neuzil KM, Onchee Y, Benson P, Barlow WE, Adams AL, et al. Effectiveness of pneumococcalpolysaccharide vaccine in older adultsexternal icon. N Engl J Med. 2003 May 1;348(18):1747-55.Jacobson SH, Sewell EC, Allwine DA, Medina EA, Weniger BG. Designing pediatric vaccine formularies and pricing pediatric combination vaccines using operations research models and algorithmsexternal icon. Expert Rev Vaccines. 2003 Feb;2(1):15-9.Kelly WN. The quality of published adverse drug event reportsexternal icon. Ann Pharmacother. 2003:37(12):1774-1778.Kohl K, Bonhoeffer J, Chen R, Duclos P, Heijbel H, Heininger U, et al. The Brighton Collaboration: Enhancing comparability of vaccine safety dataexternal icon. Pharmacoepidemiol Drug Saf. 2003 Jun;12(4):335-40.Lloyd JC, Haber P, Mootrey GT, Braun MM, Chen RT, and VAERS Working Group. Adverse event reporting rates following tetanus-diphtheria and tetanus toxoid vaccinations: Data from the Vaccine Adverse Event Reporting System (VAERS), 1991-1997external icon. Vaccine. 2003 Sep 8;21(25-26):3746-50.Mell L, Davis RL, Mullooly JP, Black SB, Shinefield HR, Zangwill KM, et al. Polio extra-immunization in children less than two years old following changes in immunization recommendation[PDF – 650 KB]external icon. Pediatrics. 2003;111:296–301.Naleway AL, Belongia EA, Greenlee, RT, Kieke BA, Chen RT, Shay DK. Eczematous skin disease and recall of past diagnoses: Implications for smallpox vaccinationexternal icon. Ann Int Med. 2003 Jul 1;139(1):1-7.Tierney BC, Martin SW, Franzke LH, Marano N, Reissman DB, Louchart RD, et al. Serious adverse events among participants in the Centers for Disease Control and Prevention’s Anthrax Vaccine and Antimicrobial Availability Program for persons at risk for bioterrorism-related inhalational anthraxexternal icon. Clin Infect Dis. 2003;37:905-911.Thompson WW, Shay D, Weintraub E, Brammer L, Cox N, Anderson L, et al. Mortality associated with influenza and respiratory syncytial virus in the United Statesexternal icon. JAMA. 2003;289:179-186.Verstraeten T, Davis RL, DeStefano F, Lieu TA, Rhodes PH, Black SB, et al. Safety of thimerosal-containing vaccines: A two-phased study of computerized health maintenance organization databasesexternal icon. Pediatrics 2003;112:1039-48.Verstraeten T, DeStefano F, Chen RT, Miller E. Vaccine safety surveillance using large linked databases: Opportunities, hazards and proposed guidelinesexternal icon. Expert Rev Vaccines. 2003 Feb;2(1):21-9.Verstraeten T, Jumaan AO, Mullooly JP, Seward JF, Izurieta HS, DeStefano F, et al. A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccinationexternal icon. Pediatrics. 2003 Aug;112(2):e98-103.Wharton M, Strikas RA, Harpaz R, Rotz LD, Schwartz B, Casey CG, et al. Recommendations for using smallpox vaccine in a pre-event vaccination program: Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR. 2003;52(No. RR-7):1-16.Yih WK, Lieu TA, Rêgo VH, O’Brien MA, Shay DK, Yokoe DS, et al. Attitudes of healthcare workers in U.S. hospitals regarding smallpox vaccinationexternal icon. BMC Public Health. 2003, 3:20Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)— United States, 1991–2001. MMWR. 2003;52:(SS-1):1-24.2002Atkinson WL, Pickering LK, Schwartz B, Weniger BG, Iskander JK. General recommendations on immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP) [sections on jet injection and occupational safety regulations]. MMWR. 2002;51(RR-2):12-13,15.Black S, Lewis E, Shinefield H, Fireman B, Ray P, et al. Lack of association between receipt of conjugate Haemophilus influenzae type b vaccine (HBOC) in infancy and risk of type 1 (juvenile onset) diabetes: Long term follow up of the HBOC efficacy trial cohortexternal icon. Pediatr Infect Dis J. 2002 Jun;21(6):568-9.Bonhoeffer J, Kohl K, Chen R, Duclos P, Heijbel H, et al. The Brighton Collaboration: Addressing the need for standardized case definitions of adverse events following immunization (AEFI)external icon. Vaccine. 2002 Dec 13;21(3-4):298-302.CDC. Adverse events associated with 17D-derived yellow fever vaccination—United States, 2001–2002. MMWR 2002;51:989-993.Cetron MS, Marfin AA, Julian KG, Gubler DJ, Sharp DJ, et al. Yellow fever vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2002;51(RR-17):1-10.Chang EJ, Zangwill KM, Lee H, Ward JI. Lack of association between rotavirus infection and intussusception: Implications for use of attenuated rotavirus vaccinesexternal icon. Pediatr Infect Dis J. 2002 Feb;21(2):97-102.DeStefano F, Gu D, Kramarz P, Truman BI, Iademarco BF, et al. Childhood vaccinations and risk of asthmaexternal icon. Pediatr Infect Dis J. 2002 Jun;21(6):498-504.Ekwueme DU, Weniger BG, Chen RT. Model-based estimates of the risks of disease transmission and economic costs of seven injection devices in sub-Saharan Africaexternal icon. Bull World Health Organ. 2002; 80(11): 859–870.Gonzalez IM, Averhoff FM, Massoudi MS, et al. Hepatitis b vaccination among adolescents in 3 large health maintenance organizationsexternal icon. Pediatrics. 2002 Nov;110(5):929-34.Halsey NA. The science of evaluation of adverse effects associated with vaccinationexternal icon. Semin Pediatr Infect Dis. 2002 Jul;13(3):205-14.Halsey NA. Anthrax vaccine and causality assessment from individual case reportsexternal icon. Pharmacoepidemiol Drug Saf. 2002 Apr-May;11(3):185-7; discussion 203-4.Jackson LA, Yu O, Heckbert SR, Psaty BM, Malais D, Barlow WE, Thompson WW, and the Vaccine Safety Datalink Study Group. Influenza vaccination is not associated with a reduction in the risk of recurrent coronary eventsexternal icon. Am J Epidemiol. 2002;156 (7): 634-640.Kohl K, Bonhoeffer J, Chen R, Duclos P, Heijbel H, et al. The Brighton Collaboration: Enhancing comparability of vaccine safety dataexternal icon. Pharmacoepidemiol Drug Saf. 2003 Jun;12(4):335-40.Lathrop S, Ball R, Haber P, Mootrey G, Braun M, et al. Adverse event reports following vaccination for Lyme disease: December 1998-July 2000external icon. Vaccine. 2002 Feb 22;20(11-12):1603-8.Mullooly, J, Pearson J, Drew L, Schuler R, Maher J, et al. Wheezing lower respiratory disease and vaccination of full-term infantsexternal icon. Pharmacoepidemiol Drug Saf. 2002 Jan-Feb;11(1):21-30.Pool V, Braun MM, Kelso JM, Mootrey G, Chen RT, et al. Prevalence of anti-gelatin IgE antibodies in persons with anaphylaxis following measles-mumps-rubella vaccine in the U.Sexternal icon. Pediatrics. 2002 Dec;110(6):e71.Pless R. Hibbs B. Chiropractic students attitudes about vaccination: A cause for concern? external iconCMAJ. 2002 Jun;166(12):1544-5.Setia S, Mainzer H, Washington ML, Coil G, Snyder R, et al. Frequency and causes of vaccine wastageexternal icon. Vaccine. 2002 Jan 15;20(7-8):1148-56.2001Barlow WE, Davis RL, Glasser JW, Rhodes PH, Thompson RS, et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccineexternal icon. N Engl J Med. 2001;345:656-61.Chen RT, Pless R, Destefano F. Epidemiology of autoimmune reactions induced by vaccinationexternal icon. J Autoimmun 2001;16:309-18.Chen RT, Pool V, Takahashi H, Weniger BG, Patel B. Combination vaccines: Postlicensure safety evaluationexternal icon. Clin Infect Dis 2001;33 (Suppl 4):s327-s333.Chen RT, DeStefano F, Pless R, Mootrey G, Kramarz P, Hibbs B. Challenges and Controversies in Immunization Safety. In: Peter G, Gardner P (eds). Vaccine recommendations: challenges and controversies. Infect Dis Clinics of North America 2001;15:21-39.Davis RL, Kramarz P, Bohlke K, Benson P, Thompson RS, et al. Measles-mumps-rubella and other measles-containing vaccines do not increase the risk for inflammatory bowel disease: A case-control study from the Vaccine Safety Datalink projectexternal icon. Arch Pediatr Adolesc Med. 2001 Mar;155(3):354-359.Davis RL, Lieu TA, Mell LK et al. Impact of the change in polio vaccination schedule on immunization coverage rates: A study in two large health maintenance organizationsexternal icon. Pediatrics 2001;107:671-676Destefano F, Davis RL, Chen RT. Autism and MMR vaccination: Controversy laid to rest?external iconCNS Drugs. 2001;15(11):831-7.DeStefano F, Mullooly JP, Okoro CA, Chen RT, Marcy SM, et al. Childhood vaccinations, vaccination timing, and risk of type 1 diabetes mellitusexternal icon. Pediatrics. 2001;108:e112-3.Jackson LA, Austin G, Chen RT, Stout R, DeStefano F, et al. Safety and immunogenicity of varying doses of trivalent inactivated influenza vaccine administered by needle-free jet injectorsexternal icon. Vaccine. 2001;19:4703-4709.Kramarz P, France EK, Black SB, Shinefield H, Ward JI, et al. Population based study of rotavirus vaccination and intussusceptionexternal icon. Ped Infect Dis J. 2001 Apr;20(4):410-6.Kramarz P, DeStefano F, Gargiullo P, Chen RT, Lieu TA, et al. Does influenza vaccination prevent asthma exacerbations in children?external iconJournal of Pediatrics. 2001;138(3):306-10.Lewis E, Shinefield HR, Woodruff BA, Black SB, DeStefano F, et al. Safety of neonatal hepatitis B vaccine administrationexternal icon. Pediatr Infect Dis J. 2001; 20: 1049-1054.Lieu TA, Davis RL, Capra AM, et al. Variation in clinician recommendations for multiple injections during adoptions of inactivated polio vaccineexternal icon. Pediatrics. 2001; 107:e49.Meyerhoff AS, Weniger BG, Jacobs RJ. The economic value to parents of reducing the pain and emotional distress of childhood vaccine injectionsexternal icon. Pediatr Infect Dis J. 2001;20(11):s57-s62.Rota JS, Salmon DA, Rodewald LE, Chen RT, Hibbs BF, Gangarosa EJ. Processes for obtaining nonmedical exemptions to State immunization lawsexternal icon. AJPH. 2001;91:645-48.Sewell EC, Jacobson SH, Weniger BG. “Reverse engineering” a formulary selection algorithm to determine the economic value of pentavalent and hexavalent combination vaccinesexternal icon. Pediatr Infect Dis J. 2001;20(11):s45-s56.Verstraeten T, Baughman AL, Cadwell B, Zanardi L, Haber P, Chen R and VAERS Team. Enhancing vaccine safety surveillance: A capture-recapture analysis of intussusception after rotavirus vaccinationexternal icon. Am J Epidemiol 2001; 154:1006–12.Wattigney WA, Mootrey GT, Braun MM, Chen RT. Surveillance for poliovirus vaccine adverse events, 1991-1998: Impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccineexternal icon. Pediatrics. 2001; 107(5):E83.Zanardi LR, Haber P, Mootrey GT, Niu MT, Wharton M. Intussusception among recipients of rotavirus vaccine: Reports to the vaccine adverse event reporting systemexternal icon. Pediatrics. 2001;107(6):E97.2000Belay ED, Holman RC, Clarke MJ, DeStefano F, Shahriari A, et al. The incidence of Kawasaki syndrome in West Coast health maintenance organizationsexternal icon. Ped Infect Dis J. 2000;19:828-32.Braun MM, Mootrey GT, Salive ME, Chen RT, Ellenberg SS, VAERS Working Group. Infant immunization with acellular pertussis vaccines in the United States: Assessment of the first two years’ data from the Vaccine Adverse Event Reporting System (VAERS)external icon. Pediatrics.2000;104(4):e51.Chen RT, DeStefano F, Davis RL, Jackson LA, Thompson RS, et al. The Vaccine Safety Datalink: Immunization research in health maintenance organizations in the USA. Bull WHO. 2000;78:186-194.Chen RT, Hardy IRB, Rhodes PH, Tyshchenko DK, Moiseeva AV, Marievsky VF. Ukraine, 1992: First assessment of diphtheria vaccine effectiveness during the recent resurgence of diphtheria in the former Soviet Union: Introductionexternal icon. J Infect Dis 2000;181(suppl 1):S178-S183.Chen RT, Mootrey GT, DeStefano F. Safety of routine childhood vaccinations. An epidemiological reviewexternal icon. Pediatric Drugs. 2000;2(4):273-290.Collet JP. MacDonald N. Cashman N. Pless R. Monitoring signals for vaccine safety: The assessment of individual adverse event reports by an expert advisory committee. Advisory Committee on Causality Assessmentexternal icon. Bull WHO. 2000;78(2):178-85.DeStefano F. Opportunities for population-based clinical research using data from managed care organizationsexternal icon. In: Davis JR, editor. Managed care systems and emerging infections. Washington, DC: National Academy Press, 2000;16-8.Feikin DR, Lezotte DC, Hamman RF, Salmon DA, Chen RT, Hoffman RE. Individual and community risks of measles and pertussis associated with personal exemptions to immunizationexternal icon. JAMA. 2000;284:3145-50.Izurieta HS, Thompson WW, Kramarz P, Shay DK, Davis RL, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young childrenexternal icon. N Engl J Med. 2000;342(4):232-239.Izurieta HS, Thompson WW, Shay DK. Influenza and hospitalizations in children [Letter]. N Engl J Med. 2000;342:1753.Kramarz P, DeStefano F, Gargiullo PM, Davis RL, Chen RT, et al. Influenza vaccination in children with asthma in health maintenance organizationsexternal icon. Vaccine. 2000;18:2288-2294.Kramarz P, DeStefano F, Gargiullo PM, Davis RL, Chen RT, et al. Does influenza vaccination exacerbate asthma? Analysis of a large cohort of children with asthmaexternal icon. Arch Fam Med. 2000;9(7):617-623.Kuppermann M, Nease RF, Ackerson LM, Black SB, Shinefield HR, Lieu TA. Parent preferences for outcomes associated with childhood vaccinationsexternal icon. Pediatr Infect Dis. 2000;19:129-133.Lieu TA, Black SB, Ray GT, Martin KE, Shinefield HR, Weniger BG. The hidden costs of infant vaccinationexternal icon. Vaccine. 2000;19:33-41.Pless R. Vaccination benefits, risks and safety: The need for a complete pictureexternal icon. Bull WHO. 2000;78(2):219-221.Pless R, Risher JF. Mercury, infant neurodevelopment, and vaccinationexternal icon. J Pediatr. 2000;136(5):571-573.Salmon, DA., Gangarosa EJ, Chen RT. Health consequences of exemptions from immunization laws [letter]external icon. JAMA. 2000; 283: 1141-2.Takahashi H. Need for improved vaccine safety surveillanceexternal icon. Vaccine. 2000;19(9-10):1004.Takahashi H, Pool V, Tsai TF, Chen RT. Adverse events after Japanese Encephalitis vaccination: Review of post-marketing surveillance data from Japan and the United Statesexternal icon. Vaccine. 2000: 18(26), 2963-2969.Wise RP, Salive ME, Braun MM, Mootrey GT, Seward JF, Rider LG, Krause PR. Post licensure safety surveillance for varicella vaccineexternal icon. JAMA. 2000;284:1271-1279.